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Abbreviations
AC adenylyl cyclase 
ACTH adrenocorticotrophic hormone
AgRP agouti-related peptide 
AR adrenergic receptor
BHK babyhamster kidney
CAM constitutively active mutant
DMH dorsomedial hypothalamus
DRG dorsal root ganglion
EST expressed sequence tags
GPCR Gprotein-coupled receptor
HEKcells human embryonal kidney cells
i.c.v. intra-cerebroventricular
i.v. intravenous
i.t. intrathecal
MC melanocortin
MCH melanin-concentrating hormone
MC-R melanocortin-receptor 
hMC-R human melanocortin-receptor
mMC-R mouse melanocortin-receptor
rMC-R rat melanocortin-receptor
MSH melanocyte-stimulating hormone
MTII melanotan II
NDP-MSH [Nle4, D-Phe7]-α-MSH
NPY neuropeptide Y
PCR polymerase chain reaction
POMC proopiomelanocortin
PVN paraventricular nucleus
SAR structure-activity relation
SSCP single strand conformational polymorphism
WT wild type
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Abstract
Melanocortins are peptide hormones which affect several physiological processes, such as
pigmentation, adrenal steroid production, grooming behaviour, nerve regeneration,
inflammation and body weight regulation. At least five receptors exist that mediate the
effects of melanocortins. The melanocortin receptors belong to the large family of G
protein-coupled receptors (GPCRs) and all activate Gs, resulting in increased intracellular
cyclic AMP levels. Not for all effects of melanocortins, the melanocortin receptor subtype
that is involved has been identified, which can partially be ascribed to the lack of receptor
subtype selective compounds. Knowing which receptor subtype mediates the
melanocortin effect would be helpful for elucidating the mechanism underlying these
effects.
Interestingly, although endogenous antagonists for GPCRs are very uncommon, two such
ligands have been identified for melanocortin receptors, namely agouti protein and agouti-
related protein.These antagonists have additional effects on melanocortin receptors that
can not be explained solely by antagonism.Therefore, it has been suggested that they may
act as inverse agonists.
This thesis focuses on the molecular pharmacological properties of melanocortin receptors,
in particular the melanocortin-4 receptor (MC4R). This centrally expressed receptor is
important for body weight regulation and food intake in rodents, but has also been
implicated to mediate melanocortin effects on grooming behaviour, nerve regeneration and
neuropathic pain. In humans, MC4R mutations have been associated with obesity, but this
has not been unequivocally proven. Better understanding the pharmacology of the MC4R
and the precise role of this receptor in different processes is valuable for determining the
potential use of the MC4R as a drug target to treat disorders related to its physiological
roles.
9
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1 Introduction to melanocortins
The melanocortins comprise a group of peptides which are derived from the
precursor proopiomelanocortin (POMC). In the beginning of the 1920’s it
was already recognized that peptides secreted by the pituitary gland regulate
pigmentation of melanophores (melanophore stimulants) but also stimulate
glucocorticoid production by the adrenal cortex (adrenocorticotrophic
hormone, ACTH), hence the name melanocortins (reviewed in [1]).When
the sequences of ACTH and two of the melanotropic factors, α-melanocyte
stimulating hormone (MSH) and β-MSH were identified, it appeared that
they share structural similarity. α-MSH is identical to the N-terminal end of
ACTH, and the Met-Glu-His-Phe-Arg-Trp-Gly sequence of these peptides
Chapter 1
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Figure 1. Schematic overview of the processing of POMC (by prohormone convertases) into
smaller peptides, and the primary sequences of the melanocortins. Step one occurs in the anterior
lobe of the pituitary gland, while in the intermediate lobe there is subsequent processing as indicated
by step two, thus yielding different melanocortin products in these two tissues. Numbers above the
fragments correspond with the amino acid numbering of POMC after cleavage of the signal peptide.
In the table containing the primary structures of the melanocortins, the minimal sequence required
for binding and activation of melanocortin receptors, also called message sequence, is depicted in
bold. Abbreviations: sp, signaling peptide; N-term, N-terminal part of POMC; ACTH,
adrenocorticotrophic hormone; LPH, lipotropic hormone (contains β-MSH); jp, joining peptide; CLIP,
corticotropin-like intermediate lobe peptide; EP, endorphin.
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is also present in β-MSH [2]. Further studies showed that ACTH, α-MSH,
β-MSH but also the hormone β-lipotropin are produced from a common
precursor, POMC [3], which was subsequently cloned in 1979 [4]. POMC
was found to contain an additional melanotropic-like peptide, named γ-
MSH, but also the analgesic opioid β-endorphin, which is structurally
different from the melanocortins. γ-MSH contains an almost identical
melanocortin message sequence as α-MSH, β-MSH and ACTH. POMC is
expressed in the pituitary gland, where it is cleaved into the different active
peptides by prohormone convertases.This process and the primary structures
of α-MSH, β-MSH, γ2-MSH and ACTH are summarized in Fig.1.
In situ hybridisation experiments have shown that besides the pituitary
gland, POMC is expressed in the arcuate nucleus of the hypothalamus and
the solitary tract of the brainstem [5,6]. Projections containing POMC
derived peptides are found in many areas in the brain, such as nuclei within
the hypothalamus (arcuate nucleus, paraventricular nucleus), preoptic area,
thalamus, subcortical limbic centres and the brainstem [7-10], with the most
dense staining in hypothalamic areas. These data indicated that there is a
melanocortin system within the brain and that besides their effects in the
periphery (melanocyte- and adrenal stimulation), melanocortins may 
influence central processes as well. Also in the spinal cord [11,12] and the
skin [13] POMC expression has been reported, but not much is known
about the exact role of POMC in these tissues in relation to melanocortin
function.
2 Effects of melanocortins and melanocortin analogues
Before the identification of receptors for melanocortins, the melanocortins
have been reported to influence a variety of peripheral and central processes
in addition to their initial described effects on melanocytes and the adrenal
cortex.These processes include grooming behaviour in rats [14,15], learning
behaviour [16], blood pressure and heart rate [17], inflammation [18],
feeding [19,20] and nerve regeneration [21-23]. In the following, an
overview of the role of melanocortins and analogues in nerve repair,
immunomodulation, nociception and grooming is given, topics that are 
relevant for this thesis.
11
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2.1 Neurotrophic effects
Application of melanocortins stimulates functional recovery after peripheral
nerve damage. In 1980, it was shown for the first time that ACTH accelerates
recovery after sciatic nerve crush [21]. Both motor and sensory function
returned to normal levels more rapidly in ACTH-treated animals.
Subsequently, many melanocortins and melanocortin analogues, including
α-MSH and [Nle4, D-Phe7]-α-MSH were shown to enhance functional
recovery [22,24-26]. The minimal sequence still active in recovery was
ACTH(4-9) [24], which contains the message sequence that is shared by all
melanocortins. Increased numbers of axons, larger motor endplates and an
increased initial neurite sprouting response are reported effects of
melanocortins [21,27-29], and application of melanocortin ligands is
effective only when started within days after nerve injury [30]. However, the
exact mechanism via which melanocortins exert their effects is unknown. In
vitro studies showed that melanocortins can stimulate neurons directly, which
suggests that melanocortins may act directly on injured neurons by
stimulating formation of new functional nerves distal of the injury. For
example, both spinal cord slices and dorsal-root ganglia cells increase neurite
outgrowth in response to α-MSH [31], and this seemed to be a cyclic-AMP
mediated mechanism [23]. Trophic effects on other types of neurons have
also been described [23].Another possible mode of action of melanocortins
could involve glial cells, which are important neurosupporting cells.
Astrocytes indeed respond to melanocortins [32], and production of
proinflammatory mediators by microglia is inhibited by melanocortin
peptides [33], which could lead to a diminished immune response to the
nerve injury. It has been suggested that the immune system causes secondary
damage at the lesion site [34], and inhibition of microglia activation could
therefore be beneficial for repair. It is also possible that melanocortins have
a direct effect on immune cells to affect neuronal repair.This should thus be
a suppressing effect, which seems in line with the anti-inflammatory
properties of melanocortins [18]. Given the complexity of the process of
nerve repair, it is conceivable that multiple mechanisms are involved
concurrently in the neurosupportive effects of melanocortins.
There is evidence that endogenous melanocortins play a role in nerve
regeneration, since a melanocortin antagonist, as identified by its ability to
Chapter 1
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block α-MSH-induced grooming, delayed recovery after sciatic nerve crush
[35].These endogenous melanocortins may be produced by the spinal cord
or dorsal-root ganglia, both sites with reported POMC expression [12].
Indeed, increased POMC mRNA and increased melanocortin
immunoreactivity seem to result from nerve damage in rats and mice
[36,37], although this was not reproduced by others [12].
In conclusion, although exogenous melanocortins clearly stimulate nerve
regeneration, the site of action and the role of endogenous melanocortins are
still unknown.
2.2 Immunomodulatory effects
Central or peripheral administered melanocortins suppress inflammation in
several models, such as injection of inflammatory stimulants
(lipopolysacharide or urate chrystals) or inflammation mediators (cytokines)
and in experimental arthritis [18].Therefore, melanocortins may prove to be
useful anti-inflammatory drugs for treatment of several disorders, for instance
of chronic inflammation and sepsis [38].
There are several proposed modes of action via which melanocortins
influence the immune system. Direct interactions with peripheral immune
cells have been described, resulting in inhibited release of (pro-
inflammatory) cytokines and nitric oxide. For instance, α-MSH inhibits
TNF-α production by mononuclear cells and stimulates IL-10 (suppressor
of cytokine production) release by monocytes. Melanocortin receptors are
expressed by several peripheral immune cells, including monocytes and
lymphocytes [39,40], suggesting that the effects of melanocortins are
mediated by these receptors. However, it should be noted that the COOH-
terminus of α-MSH (α-MSH(11-13)) is also effective in suppression of
inflammation, although this peptide does not bind any of the cloned
melanocortin receptors.This suggests that other pathways not involving one
of the cloned melanocortin receptors may be used by melanocortins.
Otherwise, α-MSH and α-MSH(11-13) could have different modes of
action.
Centrally applied melanocortins also affect peripheral inflammation.
Intracerebroventricular (i.c.v.) injections of α-MSH, reduced ear
inflammation induced by injection of inflammation mediators into the ear
13
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[41], but this effect was not seen after dissection of the spinal cord and after
peripheral administration of β2-antagonists.Thus, descending pathways using
β2-adrenergic receptors mediate the effects of central α-MSH on the
periphery.
α-MSH also inhibits inflammation within the brain. I.c.v. applied α-MSH
inhibited lipopolysaccharide-induced central TNF-α release [42].TNF-α is
produced by glial cells which are probably the targets for melanocortins in
the brain. As described above, α-MSH inhibits microglial activation [29],
suggesting that these cells indeed are involved in this effect of melanocortins.
Thus, melanocortins inhibit inflammatory processes via several mechanisms,
but complete understanding of the exact targets and the identification of the
melanocortin receptor that is involved needs further research.
2.3 Nociceptive effects
The melanocortin peptides as well as β-endorphin are cleaved from the
POMC molecule. This prompted several investigators to study possible
interactions between the melanocortin system and the opioids, which are
well known for their effects on nociception. It was found that peripheral or 
central injection of ACTH blocks morphine-induced analgesia in rats as
measured by latency time of paw withdrawal on a hot plate [43,44]. Also,
opiate tolerance that is developed after repeated opioid application, was
blocked by α-MSH [45]. These data show that melanocortins can interact
with nociceptive pathways, but direct effects of melanocortins on
nociception have also been described. Sandman and Kastin [46] reported 
hyperalgesia in the tail-flick test upon i.c.v. injection of α-MSH. A similar
effect was shown for i.c.v. injected ACTH [47]. Analgesic effects by central
injection of α-MSH have been described by some studies [48,49], but most
studies suggest that melanocortins increase sensitivity to painful stimuli, in
line with their functional antagonism on opioid-induced analgesia. The
mechanisms underlying these effects are poorly understood, but this could
be advanced by using receptor subtype-selective compounds.
2.4 Grooming behaviour
When exposed to mild stress, like being put in a novel environment, rats
display grooming behaviour [50], which involves scratching and licking of
Chapter 1
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the body surface. It was proposed that this behaviour functions to reduce
arousal after (mild) stress, which can be distinguished from grooming
committed to cleaning and maintenance of the fur. I.c.v. injection of
melanocortin ligands induces grooming resembling that of novelty-induced
grooming [14].This effect seems independent of the adrenal gland, which is
also stimulated by ACTH, since hypophysectomy and adrenalectomy did not
influence ACTH-induced grooming [51] and peripheral injections were
ineffective [52]. Proposed sites of action of melanocortins on grooming
behaviour are the substantia nigra, periaquaductal grey and the
paraventricular nucleus [50]. Endogenous melanocortins may be involved in
this process, since antibodies against melanocortins and antisense POMC
oligonucleotides inhibited novelty-induced grooming. In addition,
melanocortin antagonists inhibit grooming behaviour [53]. The grooming
assay has especially been useful to test many melanocortin analogues for in
vivo biological activity [14,54].
In conclusion, there is evidence for involvement of melanocortins in
immunomodulation, nociception, grooming behaviour and nerve recovery.
Melanocortin compounds are interesting candidates for treating disorders
related to these diverse processes, but more detailed knowledge about the
mechanisms by which these effects are achieved is needed before
melanocortin based drugs can be developed.
3 Melanocortin receptors
The concept that the effects of melanocortins would be mediated by specific
melanocortin receptors expressed by their target tissues was first explored on
cultured melanoma cells, but when the stable radioligand 125I-[Nle4, D-Phe7]-
α-MSH became available, it could be studied in whole animals as well [55].
In the mouse, specific binding sites were discovered in many tissues,
including brown and white adipose tissue, duodenum, skin and the
hypothalamus, a distribution that is similar to that observed in rats.All these
tissues are possible target sites for melanocortins, which seemed to be in line
with the variety of biological activities of melanocortin peptides. In situ
displacement studies already indicated that at least in the brain, multiple
receptor forms exist [56], and not long thereafter five receptor subtypes were
15
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cloned, at least three of which are expressed in the brain.
The first receptors to be cloned were the skin and adrenal melanocortin
receptors [57,58] which were named MC1R and MC2R, respectively.These
are the receptors that mediate the effects of α-MSH and ACTH on
melanogenesis by melanocytes and glucocorticoid production by the adrenal
gland, respectively. Subsequently, three additional receptor subtypes were
found  both in humans and rodents [59-65]. These receptors were named
MC3R, MC4R and MC5R after their chronological order of identification.
All five receptors are seven-transmembrane, G-protein coupled receptors
(Fig. 2) that couple to Gs to increase cyclic-AMP as intracellular secondary
Chapter 1
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Figure 2. Snake-like representation of the human MC4R.The architecture resembles that of other
G-protein coupled receptors in that the receptor contains seven hydrophobic domains that form the
transmembrane regions, three intracellular and three extracellular loops, a N-terminal domain and a
C-terminal domain.The cell membrane is indicated by the horizontal lines. Grey circles denote the
positions of natural occurring mutations that have been found by genetic screening (see Table II). For
frameshift mutations, the deletion mutations are denoted by “∆”, and insertions by “ins”, followed by
the sequence that is deleted or inserted, respectively.
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messenger. Apart from the MC2R, which is only stimulated by ACTH, the
melanocortin receptors respond to the endogenous melanocortins (Table I).
The cloning of these receptors has allowed better anatomical studies of
receptor distribution. Also, generation of mouse strains that lack a MCR
subtype gave more insight into the mechanisms of melanocortins, and even
new effects of melanocortins were discovered, as will be discussed below.
3.1 Melanocortin-1 and melanocortin-2 receptor
The MC1R was originally cloned from melanoma cells and has a similar
pharmacology as the endogenous receptor expressed by melanoma cell lines
[1,57]. This suggested that the MC1R is the receptor that mediates the
melanogenic effects of α-MSH and other melanocortin agonists. Indeed, the
extension locus, which affects pigmentation in mice, was found to encode the
MC1R [66]. The absence of black pigment in mice homozygous for a 
recessive e/e allele of the extension locus was caused by a frameshift mutation 
leading to a nonfunctional truncated receptor [66]. Other extension alleles
leading to a dark coat, like Esombre appeared to encode constitutively active
MC1Rs [66].These studies indicate that the MC1R indeed is the receptor
subtype involved in the melanogenic effects of melanocortins, and that
MC1R activation results in formation of more black eumelanin. MC1R
activity is regulated by agonists like α-MSH [67] and the endogenous 
antagonist agouti protein (see below), which both are locally produced in the
skin.There is evidence that in humans the MC1R is also involved in skin
17
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Table I.
IC50 values (nM) of the melanocortins for the human receptors. “-“ indicates that no displacement
of [125I]-ACTH was observed. a[194], b[72], c[195], d[196], e[197].
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and hair color, since variations in the MC1R gene occur more frequent in
humans with red hair and fair skin as compared to individuals with brown/black
hair [68]. Some of these mutations impair MC1R function [69], consistent with
a role for this receptor in the production of dark pigment.
The MC1R is also expressed in the periaquaductal grey, albeit in only a few cells
[70], and in macrophages, monocytes, neutrophils and astrocytes [71].The exact
function of the MC1R in these tissues is yet unclear, but could obviously be
related to the effects of melanocortins on the immune system.
The MC2R is mainly expressed in the cortex of the adrenal gland, which is the
site of glucocorticoid production.The MC2R distinguishes itself from the other
MCR subtypes in that it has affinity for ACTH, but not for the other
melanocortins or melanocortin analogues [72].The main role of the MC2R is
to induce glucocorticoid production by the adrenals in response to ACTH
secreted from the pituitary. Indeed, missense mutations in the human MC2R are
associated with isolated glucocorticoid deficiency syndromes [73,74]. In murine
adipocytes, also expression of MC2R was found [75], making the MC2R a good
candidate to mediate the lipolytic effect of ACTH on adipocytes.This is probably
not the case in humans, since in human adipocytes the MC2R was not detected
[76] and ACTH was ineffective in inducing a lipolytic effect [77].
3.2 Melanocortin-3 receptor
MC3R mRNA is found in the brain, placenta, duodenum,pancreas and stomach
[59,62]. In the brain, the highest expression level is found in the arcuate nucleus
and the ventromedial nucleus of the hypothalamus, the 
lateral and posterior hypothalamic area and in the medial preoptic area [62].
Recently, expression in murine macrophages has also been reported [78]. The
precise roles of the MC3R in these different tissues are poorly understood, but
in macrophages, the MC3R has been suggested to reduce 
pro-inflammatory cytokine release [78]. Mice lacking the MC3R are
hypophagic and have increased fat mass, whereas lean mass is reduced [79].This
shows that the MC3R plays a role in energy homeostasis, but how is not known.
Since the MC3R is expressed on POMC and AgRP neurons in the arcuate
nucleus of the hypothalamus [80], it may play a role in autoregulation of these
neurons. Thus, the MC3R may have its effect on energy homeostasis by
modulating the release of POMC products and AgRP.
Chapter 1
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3.3 Melanocortin-4 receptor
The MC4R is primarily expressed in the central nervous system [60].
Although it is less abundant in the brain as the MC3R, its distribution is
more widespread. In virtually all brain areas including the cortex, thalamus,
hypothalamus and brain stem, but also in the spinal cord, mRNA for the
MC4R has been found [12,81].The MC4R plays an important role in body
weight regulation, as indicated by several lines of evidence. The highest
MC4R expression is found in the paraventricular nucleus (PVN) of the
hypothalamus, a site that is involved in feeding behaviour. More direct
evidence comes from MC4R-deleted mice (MC4R -/-), which display
maturity onset obesity accompanied with hyperphagia, hyperinsulinemia
and hyperglycemia [82]. Heterozygous knockout mice had intermediate
body weight as compared to MC4R -/- and wild type mice, indicating a
gene-dosage effect. In line with these findings, food intake is inhibited by
melanocortin agonists [19,20,83], whereas in MC4 -/- mice a very potent
melanocortin agonist was ineffective [84]. Further studies showed that the
obesity in the MC4R -/- mice is due to a metabolic defect, since pair-fed
MC4R -/- mice had intermediate body weight between ad libitum fed
MC4R -/- and wild type animals [85]. In addition, young MC4R -/-
animals that had not yet developed hyperphagia already showed increased
body weight. Taken together, the data demonstrate that MC4R activation
decreases food intake and increases energy expenditure and that disruption
of MC4R signaling results in overweight.
Expression of the MC4R is also found in brain regions that are critical for
melanocortin-induced grooming in rats, i.e. the paraventricular nucleus,
substantia nigra and periaqueductal gray, suggesting that the MC4R is
involved in this process [50,64].This was confirmed by use of compounds
that show selectivity for the MC4R [86].
As mentioned above, the MC4R is also expressed in the spinal cord.
Melanocortin binding sites within the spinal cord were mainly found in
lamina X and substantia gelatinosa, areas involved in nociception [12]. Using
a chronic constriction injury (CCI) of the sciatic nerve as a model for
neuropathic pain, Vrinten et al. found that intrathecal injections of
melanocortin agonists increase mechanical and cold allodynia in rats [87].
Nle4-γ-MSH (MC3R-selective) was ineffective, and a MC3R/MC4R
19
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antagonist decreased the allodynia, suggesting involvement of the MC4R.
Changes in the melanocortin system in the neuropathic pain state were
suggested  by increased [125I]-NDP-MSH binding dorsal horn.
3.4 Melanocortin-5 receptor
The MC5R is expressed in many peripheral tissues, including skin, spleen,
lung, liver, stomach, lacrimal glands, sebaceous glands and adrenal glands
[61,63,65,88,89]. Also in the brain, expression of the MC5R has been
described [63], but this is probably at a very low level.The MC5R knockout
mouse has impaired exocrine gland function, as seen by their decreased
sebum production, leading to impaired water repulsion [90]. Since the
MC5R is the predominant melanocortin receptor present in exocrine 
tissues (lacrimal harderian and preputial glands), it is probably the receptor
that mediates most, if not all of the effects of melanocortins on these tissues,
like the stimulation of peroxidase secretion in lacrimal gland cells [91] and
preputial lipogenesis [92].
4 Melanocortin system and body weight regulation 
4.1 Agouti and agouti-related protein, endogenous
melanocortin antagonists
Mutations in a mouse chromosome locus called the “agouti” locus affect
coat colour in mice, and for some alleles (e.g. the lethal yellow (Ay) allele),
this is accompanied with an obese phenotype. Unraveling the molecular
basis for these phenotypes started with the identification of the 131 amino
acids long agouti protein, which is encoded by the agouti locus [93]. The 
yellow/obese phenotype of Ay mice appeared to result from ubiquitous over-
expression of agouti protein [94,95], which was later confirmed using
transgenic over expression of agouti protein (Fig. 3).
Agouti protein is an antagonist for melanocortin receptors, with preference
for the MC1R and MC4R [96-98].Thus, the yellow fur of the Ay animal is
due to blockade of α-MSH function at the MC1R (encoded by the
extension locus) [99], and the obesity results from blockade of the
hypothalamic MC4R.The obese phenotype of the Ay mouse is very similar
to that of the MC4R -/- mouse, supporting that blockade of the MC4R is
Chapter 1
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indeed the mechanism by which agouti induces obesity. Agouti has been
shown to inhibit cAMP formation [100,101], melanogenesis [102,103] and
tyrosinase activity [101] independent of α-MSH and therefore it was
suggested that agouti is an inverse agonist for the MC1R [102]. In addition,
Ollmann et al. showed that full-length agouti down-regulates MC1R
signaling and that the N-terminal part of agouti is needed for this effect
[104], whereas the COOH-terminus acts solely as a competitive antagonist
at the MC1R. Furthermore, by crossing the Ay allele and Mc1re allele (loss
of function of the MC1R) into a mouse strain that is sensitized for
distinguishing subtle coat colour differences, it was shown that Mc1re mice
have more pigment than mice that do express the MC1R, but which over-
express agouti [99].Thus, the effects of agouti on coat color may not only
be attributed to antagonism of α-MSH at this receptor.
A protein with a cysteine spacing in the COOH-terminus homologous to
agouti (Fig. 4) was identified from the expressed sequence tags (EST) 
21
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Figure 3. Mice with transgenic
over-expression of AgRP (top)
or agouti (bottom) and their
non-transgenic littermates. Both
transgenic animals are obese,
resulting from blockade of the
MC4R. Note that transgenic
over-expression of agouti, but
not that of AgRP results in
lighter coat colour, in line with
the high affinity of agouti for the
MC1R, but low affinity of AgRP
for this receptor. Abbreviations:
Tg, transgenic. Picture was
kindly provided by prof. dr. G.
Barsh.
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database and was named agouti-related protein (AgRP) [105,106]. AgRP is
an antagonist for the MC3R and MC4R [106,107], and is expressed in the
arcuate nucleus of the hypothalamus and the adrenal gland [105,108]. Similar
to agouti protein, the cysteine-rich COOH-terminus is sufficient for
interaction with the melanocortin receptors [106,109,110]. The down-
regulation of MC1R signalling in the Xenopus melanophore assay as
observed for agouti was not seen with full-length AgRP, but in this frog assay
AgRP acted solely as a competitive antagonist on the MC1R [104]. AgRP
is an orexigenic signalling molecule that acts most likely via blockade of
MC4Rs and/or MC3Rs in the brain. Its role in body weight regulation was
indicated by several lines of evidence. For example, the mRNA for AgRP is
upregulated in obese mutant mice [105], over-expression of AgRP results in
an obese phenotype which resembles that of the Ay mouse [111] (Fig. 3) and
i.c.v. injections of AgRP or its COOH-terminus increase food-intake
[112,113]. In humans,AgRP may also play a role in body weight regulation,
since a polymorphism in the coding region of the AgRP gene was recently
found to be associated with anorexia nervosa [114]. Interestingly, increased
food intake is still evident 6-7 days after a single i.c.v. injection of AgRP
[115,116] and this long term effect seemed not to occur via antagonism of
melanocortins [115].Also in vitro,AgRP has properties that are incompatible
with pure antagonism, such as decreasing basal cAMP levels and the maximal
response to α-MSH in cells that express the MC4R [106,110,117].
Therefore, AgRP may have functions beyond antagonizing α-MSH, similar
to agouti.
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Figure 4. Alignment of the amino acid sequences of human AgRP and mouse agouti.The highest
degree of homology is found in the cysteine rich C-terminal part of the molecules, which is the part
that binds melanocortin receptors. Arrows indicate signal sequence cleavage sites.
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4.2 Neuroanatomical basis of the melanocortin system in body
weight homeostasis
The brain melanocortin system comprises neurons that produce AgRP or
melanocortin agonists, which project to neurons containing MC3Rs and/or
MC4Rs. As outlined in the sections above, both AgRP and the POMC-
derived melanocortins are produced by neurons in the arcuate nucleus of the
hypothalamus, but it has been shown that they are produced by separate cell
populations [118,119]. AgRP neurons have been shown to express also the
orexigenic peptide neuropeptide-Y (NPY), and POMC neurons co-express
the anorexigenic peptide cocaine-amphetamine regulated transcript
(CART) [119-122].
The mRNA levels for POMC and AgRP are regulated by the energy state
of the organism. A period of fasting results in increased levels of AgRP
mRNA and decreases in POMC mRNA [123,124], which seems the 
appropriate response to a negative energy balance. Conversely, overfeeding
causes upregulation of POMC mRNA [125].These effects of feeding seem
to be mediated by leptin, an adipose tissue-derived hormone that decreases
food intake when applied exogenously [113,126]. Receptors for leptin are
found on AgRP and POMC neurons [118,127], and exogenous application
of leptin increases POMC mRNA, whereas mRNA for AgRP is decreased
[118,123,124,128,129]. Furthermore, ob/ob mice, which are deficient for
leptin, have decreased levels of POMC mRNA and increased levels of AgRP
mRNA [105,113,128]. Plasma leptin levels correlate with long term changes
in amount of body fat, but are also regulated by more acute changes in the
energy state. Upon fasting, leptin levels are rapidly decreased [130], which
would result in less stimulation of POMC neurons and decreased inhibition
of AgRP neurons, corroborating with the effect of fasting on these neurons.
The melanocortin system appears to be an important target for leptin 
signalling, since the inhibitory effect of leptin on food intake was blocked by
AgRP and the MC3R/MC4R antagonist SHU9119 [113,131].Thus,AgRP
and POMC neurons in the arcuate nucleus of the hypothalamus are 
controlled by leptin, which stimulates POMC neurons and inhibits AgRP
neurons.
Projections that contain AgRP or melanocortins are found in several areas
that are important for body weight homeostasis, such as the paraventricular
23
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nucleus (PVN), the dorsomedial nucleus (DMH), the lateral hypothalamus,
but also within the arcuate nucleus itself [118,132]. In the lateral
hypothalamus, their terminals connect to neurons that contain orexin and
melanin-concentrating hormone-containing [122,133] and in the PVN to 
thyrotropin-releasing hormone (TRH) neurons [134], all known to be
involved in body weight homeostasis. Virtually all areas with AgRP
immunoreactivity also contain melanocortinergic projections, but the latter
are also found in areas that are not innervated by AgRP, such as the
brainstem, hippocampus and amygdala [80,118,132,133]. The presence of
AgRP and melanocortinergic terminals in areas with high MC3R/MC4R
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Figure 5. Schematic anatomical overview of the brain melanocortin system that is involved in body
weight regulation. Leptin is produced by adipose tissue and secreted into the blood. It enters the
arcuate nucleus (Arc), where it inhibits orexigenic AgRP/NPY neurons and stimulates anorexigenic
POMC/CART neurons.These neurons project within the Arc itself and to several other areas that
contain MC3Rs and MC4Rs (paraventricular nucleus, PVN; lateral hypothalamus, LH) where they
most likely modulate expression of these neuropeptides. Melanin concentrating hormone, MCH;
orexins, ORX; thyrotropin-releasing hormone,TRH.
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expression supports that the effects of AgRP on food-intake are mediated by
these receptors. A schematic overview of the relation between AgRP and
POMC neurons, their input signals and projections is given in Fig. 5.
4.3 Human genetics of the Melanocortin-4 receptor
Several genetic studies have addressed the question whether the MC4R also
regulates body weight in humans. In 1998,Yeo et al [135] and Vaisse et al
[136] were the first to describe mutations in the MC4R gene that were 
associated with obesity in humans. Both studies reported a frameshift 
mutation that resulted in a nonfunctional receptor [137]. Subsequent studies
have identified many additional heterozygous mutations in the human
MC4R gene [138-149]. Together, these studies have analyzed the coding
sequence of the MC4R gene of 1582 obese and 481 non-obese individuals,
in which 32 different mutations were identified (Table II and Fig. 2). The
majority of the mutations, not including the V103I and I251L
polymorphisms that show no difference in frequency between obese and
non-obese populations [138,146], have only been found in obese
individuals, suggesting causality between mutations in the MC4R and
development of obesity. Of the 1582 obese individuals, 34 contain a MC4R
mutation, which is 2.1%, and this would make it the most common
monogenic form of obesity.To determine penetrance of individual MC4R
mutations, family studies have been carried out for a number of these
mutations. Although the majority of family members with a MC4R
mutation are obese [140-143,147,148] statistical significance was only
indicated for one frameshift mutation [135,148]. For the other mutations,
reduced penetrance and variable phenotypes of mutation carriers were
found.This is probably the result of differences in degree of loss of function
between mutant alleles but may also be due to other genetic or
environmental factors that influence body weight. For example, obese non-
carriers were found in several families, indicating that these families are
already predisposed for obesity [143,148]. As a result, the impact of the
MC4R mutations on obesity could not be assessed in these families.Also, less
severe obesity was observed in carriers that belong to a family of which non-
carriers have a body mass index (BMI) below the 50th percentile [148],
indicating that the quantitative effect of MC4R mutations on body weight
25
Introduction
proefschrift wouter  04-02-2003  16:24  Pagina 25
Chapter 1
26
Table II.
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is influenced by other factors. Even more, there have been reports of lean
individuals which miss one MC4R allele or which carry a frameshift
mutation which most likely results in a nonfunctional receptor.Thus, missing
one functional allele of the MC4R does not always lead to obesity and
therefore the relevance of heterozygous MC4R mutations for body weight
regulation in humans remains equivocal.
Functional characterization of mutant receptors helps to determine the
27
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Table II (continued).
Summary of pharmacological data and family studies of the mutations that have been found mostly
in obese individuals. For the silent mutations, the number refers to the base sequence, for the other
mutations the number indicates the codon at which the mutation occurs.When available, the effect
on EC50 and Kd values and the maximal effect  (Emax) of α-MSH (MSH) or [Nle4, D-Phe7]-α-MSH
(NDP) as compared to the wild type receptor is given, followed by the factor by which these values
differ from those of the wild type receptor. Equal EC50 and Kd values are denoted by “=”, and
increases or decreases by “↑” and “↓”, respectively. Non-obese indicates that anorexia nervosa or
bolumia nervosa patients belong to the group [139].
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importance of the mutations for development of obesity. Loss of function is
to be expected from MC4R mutations that lead to obesity. Indeed, two of
the frameshift mutations result in complete loss of function proteins [137]
and most of the missense mutations that have been tested functionally,mostly
in activation assays, were found to have decreased response to α-MSH (Table
II). On the other hand, the two polymorphisms did not differ from the wild
type receptor in affinity for, and response to α-MSH and AgRP [137],
indicating that only functionally relevant mutations predispose for
overweight. Though, more detailed information on the effect of the
mutations for receptor function and more patient data are needed before
such correlations can be made.
5 Synthetic melanocortin compounds
Potent and selective ligands are very powerful tools to study the 
physiological roles of hormonal and neuropeptide systems. Before the
cloning of the melanocortin receptors, very potent agonists were developed
by use of the frog and lizard melanophore pigment dispersion assay, which
have improved our knowledge on the physiological roles of melanocortins.
Antagonists have been unavailable for a relatively long time, but eventually
these were developed and have been used in studying the roles of the 
different melanocortin receptors.The minimal active sequence was found to
be Ac-His-Phe-Arg-Trp-NH2 [150], and therefore the search for new
melanocortin ligands has mainly focused on this part of the sequence.
Replacing Met4 and Phe7 of α-MSH with Nle and D-Phe, respectively,
resulted in [Nle4, D-Phe7]-α-MSH (NDP-MSH), which is more resistant to
heat and enzymatic degradation, but also has increased potency and 
prolonged activity (probably due to slow dissociation from the receptor
[151]) as compared to α-MSH [152] (Table III).The radioactive iodinated
form of NDP-MSH has become the most widely used melanocortin 
radioligand for in situ binding- and in vitro experiments to determine affinity
of compounds for MCRs. Furthermore, because of its stability, NDP-MSH
has been used to study the role of melanocortins in vivo, for example in
interleukin-1 responses, body temperature regulation, melanogenesis in
human melanocytes, haemodynamics, hypothalamo-pituitary thyroid axis
and feeding [153-158]. In 1982, Sawyer et al [159] found that a cyclic
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homologue of α-MSH, [Cys4, Cys10]-α-MSH, is very potent in the
melanophore assay and has prolonged activity.This suggested that the cyclic
molecule resembles the active conformation of α-MSH, and it was proposed
that a β-turn in α-MSH is important for biological activity, which was later
confirmed with NMR studies [160,161]. Cyclic compounds were also
produced by formation of a lactam bridge between position 4 and 10, as in 
Ac-Nle4-c[Asp5, D-Phe7, Lys10]-α-MSH(4-10), also named MTII [162]. In 
physiological studies, MTII has mainly been used to assess the role of the
melanocortin system in body weight regulation [83,84,115,163]. By 
substitution of D-Phe of MTII with D-Tyr, a MC4R-selective agonist was
obtained,which has been used to imply the MC4R in grooming behaviour [86]
Antagonists are useful in that they can be used to determine whether
endogenous ligands play a role in physiological processes and to block
exogenous applied ligands to control for receptor specificity. [D-Arg7, Ala8,
D-Phe10]-α-MSH(6-11) was one of the first melanocortin antagonists, and
29
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Pharmacological data of the most important synthetic melanocortin compounds for the different
melanocortin receptors.These studies did not include the MC2R because it can not be expressed
in most cell lines and because this receptor only binds ACTH.“*” denotes partial agonism; antagonists
for which no KB value is available, but blockade of the α-MSH response was shown are indicated by
“anta”.
Table III.
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was identified in frog and lizard skin darkening assays. The screening of a
library of ACTH(4-10) analogues resulted in the identification of four
melanocortin antagonists with pA2 values of 8.7-<6 nM at the MC3R,
MC4R and MC5R [164] and three of these antagonists blocked α-MSH-
induced grooming. The most widely used antagonist is SHU9119, which
was obtained by substituting the D-Phe7 of MTII with the bulky amino acid
D-Nal(2) [165]. It is an antagonist for the MC4R, a weak partial agonist for
the MC3R, and a full agonist for the MC1R and MC5R, but is nonselective
with regard to affinity (Table III). SHU9119 has been used to block
MC3R/MC4R-mediated melanocortin effects, like food intake, inhibition
of inflammatory responses and cardiovascular responses [78,83,131,166].
MC4R-selective antagonists have also been developed [167-169] (see Table
III).These comprise cyclic disulfide bridged peptides with a D-Nal(2) on the
position that aligns to position 7 of α-MSH. HS014, which is 17-fold 
selective for the MC4R as compared to the MC3R and even more selective
as compared to the MC1R and MC5R, has been used mainly to implicate
involvement of the MC4R in food intake [170-172], but also the effects on
grooming have been studied [173,174].
Taken together, the available melanocortin compounds have increased our
understanding on the physiological roles of melanocortins and their 
receptors, but especially agonists with increased selectivity for any of the
other receptor subtypes are still lacking.
6 Inverse agonism
Classical theory of G-protein coupled receptor (GPCR) activation predicts
that a receptor is inactive under basal conditions, and that agonist binding
induces a conformational change towards the activated state of the receptor.
Antagonists, on the other hand, do not activate the receptor, but prevent
agonist binding by occupying the receptor. In 1989, Costa and Herz [175]
found that a δ-opioid antagonist could inhibit basal activity displayed by the
receptor. They also showed that this “negative intrinsic activity” could be
blocked by ligands that do not have this property. Since care was taken that
the basal activity was not due to contaminating agonist, their conclusion was
that in contrast with the old concept, receptors can be active in the absence
of agonist ligand, and that this constitutive receptor activity can be 
Chapter 1
30
proefschrift wouter  04-02-2003  16:24  Pagina 30
inhibited by some, but not all antagonists. Antagonists that decrease
constitutive receptor activity were later re-classified as inverse agonist. For
many GPCRs, including β2-adrenergic receptors [176], serotonin 5-HT2C
receptors [177], histamine receptors [178] and dopamine D5 receptors [179],
inverse agonists have been found, showing that it is a general phenomenon.
There is evidence that inverse agonists have higher affinity for the inactive
state of the receptor as compared to the inactive state. For instance, by
uncoupling the receptor from the G-protein and forcing it into the inactive
conformation (by use of e.g. pertussis toxin for Gi coupled receptors or 
guanine nucleotides), increased affinity of inverse agonists for these receptors
have been measured [175,180]. Conversely, mutated receptors which display
high constitutive activity show decreased affinity for inverse agonists as 
compared to the less constitutively active non-mutated receptor, whereas the
affinity of (partial) agonists for these receptors was increased. [181] The
increase in affinity of agonists correlated with the intrinsic activity of the
ligands.Antagonists, on the other hand, did not have altered affinity for these
constitutively active receptors. The most widely used, though simplified
model to describe these findings is the two-state receptor model (Fig. 6).
A common problem in studies on inverse agonists is that constitutive 
activity is usually low, making it difficult to distinguish inverse agonists from
neutral antagonists. Over-expression of receptors increases the amount of
measurable constitutive activity and thus can be used to more sensitively
detect inverse agonism [176,182,183]. Milano et al. [184] showed that 
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Figure 6. Two-state receptor
model in which receptors are in
equilibrium between the inactive
state (R) and the active state
(R*) in the absence of agonist.
The equilibrium between these
two states determines the
degree of constitutive activity.
Ligands with preference for the inactive state (inverse agonists) will shift the equilibrium towards the
inactive state, while ligands with preference for the active state (agonists) will shift the equilibrium
towards the active state, and neutral antagonists do not distinguish between the two states and thus
will not have an effect. When there is no constitutive activity (i.e. if the equilibrium lies towards the
inactive state under basal conditions), inverse agonists will behave like neutral antagonists.
proefschrift wouter  04-02-2003  16:24  Pagina 31
cardiac over-expression of the β2-adrenergic receptor also increases basal
activity in vivo, as measured by atrial contractility and ventricular function.
Mutant receptors with increased constitutive activity (CAM receptors) have
also been used to facilitate measurement of inverse agonism [181,185].
Although the use of heterologous receptor over-expression and CAM
receptors is useful to identify and study some effects of inverse agonists, the 
physiological relevance cannot be investigated in these models. However,
inverse agonism has also been measured in more physiological relevant
preparations, such as atrial membranes (muscarinic acetylcholine receptors)
and cardiac myocytes (β2-adrenergic receptor) (for overview, see [186]),
indicating that receptors can be constitutively active in their endogenous
environment and under normal expression levels. Recently, evidence was
provided that the histamine-3 receptor displays constitutive activity in the
brain, which could be inhibited by inverse agonists [187]. Interestingly,
POMC deficient mice, which lack melanocortin agonists, still produce some
black pigment, as opposed to mice deficient for the MC1R or which 
over-express agouti protein [188].This may be due to constitutive activity of
the MC1R. Although the relevance of constitutive activity and inverse 
agonism under normal conditions remains mostly unclear, a number of 
diseases is caused by high constitutive activity of receptors [186,189]. For
example, night blindness and familial hyperthyroidism are caused by 
mutations in the rhodopsin receptor and  thyroid-stimulating hormone
receptor, respectively. Theoretically, these diseases should be treated with
inverse agonists and not antagonists, indicating possible relevance of inverse
agonism in therapy.
Apart from inhibition of constitutive activity, another property of inverse
agonists that may be relevant, is receptor regulation. Receptor activation by
agonist treatment is usually followed by a rapid decrease in cellular 
responsiveness, involving phosphorylation of the receptor.Therefore, it was
not surprising that constitutively active receptors show increased basal
phosphorylation and internalization [190,191]. Some studies describe 
upregulation of constitutively active receptors by inverse agonists, whereas
neutral antagonists did not have this effect [178,192].This was explained by
the reduction of constitutive down-regulation of the receptor by the inverse
agonist. As such, dependent on whether receptor upregulation is desired or
Chapter 1
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unwanted, an inverse agonist or a neutral antagonist will be preferred.
However, receptor up-regulation is not always correlated with inverse
agonism. For some CAM receptors, up-regulation was induced by ligands
irrespective of their nature (agonist, antagonist, inverse agonist) [193]. This
was explained by structural instability of the mutant receptors, but binding
of any ligand can stabilize the receptors.
7 Aims and outline of this thesis
The main objectives of this thesis were to characterize the molecular
pharmacological properties of the MC4R in order to allow critical
evaluation of this receptor as a drug target. As outlined above, the diverse
physiological effects of melanocortin ligands would make their receptors
interesting targets for treatment of a number of disorders, like obesity or
neuropathic pain.The molecular and cellular mechanisms underlying these
effects are mostly not well characterized and therefore better understanding
of these mechanisms, including which receptor subtypes are involved, is
important for development of melanocortin-based treatment. In chapter
two and three, the approach was to identify selective ligands for the MC4R
and use these to test the role of this receptor in grooming behaviour,
neuropathic pain and functional recovery from peripheral nerve damage.
These are processes in which the MC4R has been implicated, and by use of
selective ligands this hypothetical involvement can be tested 
functionally. In addition, knowledge on the molecular requirements for
receptor selectivity such as provided by this study is helpful for designing
drugs that interact specifically with the target receptor and thus should 
produce less side effects.
As described in chapter four, it was investigated whether the MC4R 
displays constitutive activity and whether AgRP is an inverse agonist for
melanocortin receptors.The rationale for this study comes from evidence in
literature pointing towards AgRP being an inverse agonist. First, AgRP has
high homology with agouti protein, which is suggested to be an inverse 
agonist for the MC1R (see paragraph 4).Therefore,AgRP may have similar
effects on its principle receptors, the MC3R and MC4R. Second, in some
studies AgRP decreased basal receptor activity, which is a typical property of
inverse agonists. In view of finding drugs that interact with the MC3R or
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MC4R, inverse agonism may be a relevant property to test for when
screening for melanocortin-based drugs. Furthermore, the existence of a
natural inverse agonist would add support to a physiological role of
constitutive activity and inverse agonism, which is still under debate. All
inverse agonists that have been found were not endogenous and were mostly
non-natural compounds, which is related to the fact that almost all natural
ligands are agonists.The melanocortin system thus provides a unique model,
since it is the only GPCR system for which endogenous antagonists have
been found.
Chapter five describes the pharmacological characterization of mutant
MC4Rs that have been identified in humans. Genetic studies have revealed
that heterozygous mutations in the MC4R occur more frequently in obese
individuals as compared to non-obese individuals.This suggested that also in
humans the MC4R is important for body weight regulation. If so,
individuals with obesity due to MC4R mutations, but also with other forms
of obesity could benefit from melanocortin application. The general
hypothesis is that these mutations result in decreased or defective MC4R
signaling and, in analogy to its role in rodents, therefore lead to obesity. A
number of these mutations were indeed shown to have an impaired response
to α-MSH,but no other aspects of receptor pharmacology had been studied.
In this study, for eleven of the naturally occurring MC4R mutations the
impact on receptor function was studied in more detail. These functional
data may ascertain which properties are relevant for melanocortin based
drugs, but also can help to determine the quantitative effect of the individual
mutations on body weight.
Chapter 1
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Abstract
The melanocortin-4 receptor (MC4R) is involved in several physiological processes,
including body weight regulation and grooming behaviour in rats. It has also been suggested
that the MC4R mediates the effects of melanocortin ligands on neuropathic pain. Selective
compounds are needed to study the exact role of the MC4R in these different processes.
We describe here the development and evaluation of new melanocortin compounds that
are selective for the MC4R as compared with the other centrally expressed receptors,
MC3R and MC5R. First, a library of 18 peptides, in which a melanocortin-based sequence
was systematically point-mutated, was screened for binding to and activity on the MC3R,
MC4R and MC5R. Compound Ac-Nle-Gly-Lys-D-Phe-Arg-Trp-Gly-NH2 (JK1) appeared to
be the most selective MC4R compound, based on affinity. This compound is 90-fold and
110-fold selective for the MC4R as compared to the MC3R and MC5R, respectively.
Subsequent modification of JK1 yielded compound Ac-Nle-Gly-Lys-D-Nal(2)-Arg-Trp-Gly-
NH2 (JK7), a selective MC4R antagonist with 34-fold MC4R/MC3R and 109-fold
MC4R/MC5R selectivity.The compounds were active in vivo as determined in a grooming
assay and a model for neuropathic pain in rats. Intravenous injections suggested that they
were able to pass the blood-brain barrier.The compounds identified here will be useful in
further research on the physiological roles of the MC4R.
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Introduction 
The melanocortin receptor (MCR) family consists of five receptor subtypes,
which are all seven-transmembrane receptors coupled to the adenylate
cyclase pathway. These receptors are expressed in a variety of tissues,
including brain (MC3R, MC4R, MC5R), adrenals (MC2R) and skin
(MC1R).The natural ligands which bind MCRs are the agonists ACTH, α-
, β-, and γ-MSH and the antagonistic ligands agouti protein and 
agouti-related protein [1-3]. Agouti-related protein is an inverse agonist for
the MC3R and MC4R [4,5] and there is evidence that agouti may be an
inverse agonist for the MC1R [6-8]. The endogenous ligands are not 
selective for any of the MCR subtypes, although γ-MSH possesses some
selectivity for the MC3R.Targeted deletion of MCRs in mice revealed the
importance of MCR subtypes in body weight regulation (MC4R) [9],
energy storage (both MC3R and MC4R) [9,10] and exocrine gland
function (MC5R) [11].A potential problem with these models is that other
systems may compensate for the absence of the MCRs during development.
Therefore, other approaches such as the use of receptor subtype-selective 
ligands are needed to elucidate the physiological roles of the different 
receptor subtypes. The aim of this study was to develop agonists and 
antagonists, which more selectively activate or antagonize the MC4R than
the other centrally expressed MCRs (MC3R, MC5R). First, the peptide 
Ac-Nle-Gly-His-D-Phe-Arg-Trp-Gly-NH2 was mutated at several 
positions (substituted positions are depicted in bold). The analogues were
screened for activity and affinity for the MC3R, MC4R and MC5R.
Subsequently, new analogues were synthesised to further explore the results
of this screening. We identified a MC4R-selective agonist (JK1) and a
MC4R-selective antagonist (JK7), both showing efficacy in a rat-grooming
assay. Moreover, JK1 also increased neuropathic pain behaviour in rats with
a chronic constriction injury (CCI) of the sciatic nerve.
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Materials and Methods
Synthesis of Peptides
Peptides from library I were synthesized on polyethylene pins according to
established Pepscan procedures [12]. The pins were functionalised with
amine groups to which beta-alanine and a cleavable Rink linker
(Fmoc-2,4-dimethoxy-4’-(carboxymethyloxy)-benzhydrylamine) were
coupled. The peptides were synthesized using standard Fmoc (9-
fluorenylmethoxycarbonyl) chemistry and were cleaved from the pins and
deprotected in a mixture of TFA/water/ethanedithiol/thioanisole/phenol
40/2/1/2/3 (v/v/v/v/w) for 2 h. The peptides were precipitated and
washed in ether and then lyophilized from water/acetonitrile 1/1. Purity
and identity of the peptides were assessed using liquid
chromatographic/mass spectrometric (LC/MS) analysis. For LC, a Waters X
Terra MS C18 column (2.5 µm, 4.6 x 50 mm) was used and the mobile
phase consisted of a acetonitrile/water gradient, both acetonitrile and water
containing 0.05% trifluoroacetic acid (TFA). A gradient of 5% to 65%
acetonitrile/TFA solvent in 10 minutes was used at a flow of 1.5 ml/min
and a temperature of 50°C. Products were detected with a 996 photodiode
array detector (Waters, Milford, MA) at 215 nm. MS was performed on a
Micromass ZQ mass spectrometer (Waters, Milford, MA). Purity of
compounds was found to be 70% to 95% and the masses of the products
were in agreement with the calculated values for the peptides.
The peptides (N-acetyl, C-terminal carboxyamide form) from library II
were synthesized on an automatic ABI 433A Peptide Synthesizer using the
FastMoc 0.25 mmol chemistry [13], with a coupling time of 45 min instead
of 20 min. Fmoc (9-fluorenylmethoxycarbonyl)-amino acid derivatives,
activated in situ using HBTU/HOBt and DiPEA in NMP, were used in
coupling steps.The peptide was de-protected and cleaved from the resin by
treatment with 10 mL TFA, 0.25 mL H2O and 0.25 mL TIS, for 2 h at room
temperature. Finally, the peptide was precipitated in a MTBE/n-hexane
(1/1, v/v) solution. After this, the pellet was dissolved in tert.-BuOH/water
(1/1, v/v) (ca. 60 mL) and lyophilized to obtain the crude peptide as a white
fluffy solid.The identity of the peptide was confirmed by ES-MS.
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Cell culture and transfection
Human embryonal kidney (HEK)293 cells were grown in Dulbecco’s
Modified Eagle Medium DMEM (Gibco, Paisley, Scotland) supplemented
with 10% fetal calf serum (Integro, Zaandam, the Netherlands), 2 mM 
glutamine (Gibco, Paisley, Scotland) and non-essential aminoacids (NEAA,
Gibco, Paisley, Scotland). Mouse B16/G4F melanoma cells [14] were grown
in RPMI1640 medium (Gibco, Paisley, Scotland) supplemented with 10%
fetal calf serum (Integro, Zaandam, Netherlands), NEAA and 15 mM 
sodium hydrogen carbonate.
DNA was transfected into cells with a standard calcium phosphate
precipitation protocol. Receptor cDNAs of the human melanocortin-3
receptor (hMC3R) [15], hMC4R [16] and mouse MC5R [17], each cloned
in the vector pcDNA3 (Invitrogen, Carlsbad, CA) were used.The activation
assay uses the CRE-LacZ construct described by Chen et al.[18].
B16/G4F clones stably expressing MCRs were selected with 800 µg/ml
G418 (Gibco, Paisley, Scotland) after transfection.
Binding assay
For binding experiments with peptides of library I, receptors were
transiently expressed in HEK293 cells. In experiments with peptides of
library II, B16/G4F cells stably expressing MCRs were used.
IC50 and Ki values were determined with iodinated [Nle4, D-Phe7]-α-MSH
(NDP-MSH) as tracer. NDP-MSH was iodinated using bovine lacto-
peroxidase (Calbiochem, La Jolla, CA) and 125I-Na (ICN, Aurora, OH)
according to Oosterom et al. [19] and subsequently high pressure liquid
chromatography-purified on a C18 column (µBondapak 3.9 X 300 mm,
Waters, Milford, MA).
Cells growing in 24-wells plates were washed with tris-buffered saline (TBS)
supplemented with 2.5 mM calcium chloride and incubated for 30 min at
room temperature with peptides and tracer diluted in Ham’s F10 medium
(Gibco, Paisley, Scotland) supplemented with 2.5 mM calcium chloride,
0.25% bovine serum albumine (BSA) (ICN,Aurora, USA) and 200 KIU/ml
aprotinin (Sigma, Steinheim, Germany).After two washes with ice-cold TBS
(+ 2.5 mM calcium chloride) to remove non-bound tracer, the cells were
lysed in 1M sodium hydroxide and samples were counted in a γ-counter.
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In each binding experiment, IC50 values of non-iodinated NDP-MSH were
determined to allow calculation of Ki values using the formula: Ki =
(IC50(compound)/IC50(NDP-MSH)) * Kd(NDP-MSH). The Kd values of
125I-NDP-MSH for the receptors were calculated from saturation isotherms
of 125I-NDP-MSH (two independent experiments per receptor).
Activation assay
Activation of receptors was determined using LacZ as a reportergene [18].
HEK293 cells growing in 10-cm dishes were cotransfected with 100-200 ng
receptor DNA and 7 µg of CRE-LacZ construct [18].After transfection, the
cells were plated into 96-wells plates (BectonDickinson). Two days after
plating, the cells were incubated with peptides at the appropriate
concentrations in serum-free medium (DMEM containing 0.2% BSA (ICN,
Aurora, USA) glutamine (Gibco, Paisley, Scotland) and non-essential
aminoacids (Gibco, Paisley, Scotland)). After 5-6 hours of incubation, the
assay medium was aspirated and 40 µl of lysis buffer (PBS containing 0.1%
triton-X-100 (Boehringer, Mannheim, Germany)) was added. The plates
were stored at -20°C and after thawing 80 µl of substrate mix (0,1 M
phosphate buffer, pH7.4 containing 1.6 g/l o-Nitrophenyl β-D-
galactopyranoside (ONPG, Molecular probes, Leiden, the Netherlands), 67.5
mM β-mercaptoethanol (Merck, Darmstadt, Germany) and 1.5 mM
magnesium chloride) was added. Absorbance at 405 nm was determined in
a Victor2 microplate reader (PerkinElmer, Brussels, Belgium). For
determination of pA2 values, dose-response curves of α-MSH alone or in the
presence of 0.015 – 1000 nM antagonist. Data were plotted with –log[α-
MSH] on the x-axis and log[A’/A-1] on the y-axis, where A is the EC50
value of α-MSH in the absence of antagonist, and A’ the EC50 value of α-
MSH in the presence of antagonist. After linear regression of the data the
interception with the x-axis, wich is the pA2 value, was determined.
Animals
Male Wistar rats weighing 200-240 g at the start of the study were used.
Animals were housed in groups of 2-3 in plastic cages on a sawdust bedding
and kept at a 12/12hr light/dark cycle, with food and water available ad
libitum. All testing procedures in this experiment were approved of by the
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Ethics Committee on Animal Experiments of the Utrecht University.
Neuropathic pain experiments were performed according to the Ethical
Guidelines of the International Association for the Study of Pain [20].
Grooming assay
For grooming assays, rats received an intra-cerebroventricular (i.c.v.) cannula
as described in Brakkee et al. [21] and were allowed to recover for three days.
Before the experiment, the rats were kept for at least one hour in the
experimenting room to reduce novelty-induced grooming. Grooming assays
were performed as described in Gispen et al. [22]. Briefly, observation started
10 minutes after i.c.v. or i.v. injection of compounds diluted in saline.
Grooming behaviour was scored at timepoints with intervals of 15 seconds
for a period of 60 minutes. The grooming score per rat is expressed as the
number of timepoints that the rat showed grooming behaviour. For i.c.v.
injections, 3µl of fluid was used and 100 µl volumes were used for intravenous
(i.v.) injections via the tail. To determine blocking potency of antagonists
when injected i.c.v., mixtures containing 1.5 µg α-MSH and indicated doses
of antagonist were used. For i.v. injections of antagonist, the antagonist was
applied immediately after the i.c.v. application of 1.5 µg α-MSH.
Neuropathic pain experiments
1 Surgery and drug administration
In 30 animals a peripheral neuropathy was produced by a chronic
constriction injury (CCI) of the right sciatic nerve [23]. After two weeks a
steel cisterna magna cannula was placed as previously described by [24]. 20
Control animals only received a cisterna magna cannula.
The animals were allowed a four-day recovery period before testing was
initiated, and there was at least a two-day interval between consecutive
testing days, to minimize the possibility of drug interactions or development
of tolerance.
On each testing day CCI rats were randomly divided into 3 groups (N =10
each), each group randomly and blindly receiving one of the following
doses: vehicle, MTII: 15, 30, 100 or 500 ng, JK1: 150, 500 or 1500 ng.
Compounds were dissolved in 10 µl of saline and injected through the
cisterna magna cannula by means of a Hamilton syringe.
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Alignment of NDP-MSH, MTII, [D-Tyr4]-MTII, SHU9119 and the reference peptide E8 used in this
study, to α-MSH. Numbering of positions is according to position in α-MSH. The residues of the
message sequence are given in bold.
Table I.
2 Cold and mechanical allodynia assessment 
Responses to cold and mechanical stimuli were measured as previously
described [25]. In short, for cold allodynia assessment withdrawal latencies
to immersion of the experimental hind paw into a 4.5°C water bath were
determined using an electronic timer. Cut-off time was set at 10 s.
Mechanical allodynia was measured by applying a series of von Frey
filaments (ranging from 1.08 to 21.09 g) to the midplantar surface, according
to [26]. The smallest filament eliciting a foot withdrawal response was
considered the threshold stimulus.
For both tests baseline values were determined and measurements were
repeated 15, 30 and 60 min after compound or vehicle administration.
Data analysis
IC50 and EC50 values were calculated using non-linear regression with Prism
software (GraphPad, San Diego, USA). For the peptides of library II the
average of 3 to 5 independent experiments was calculated.
Differences in grooming scores were analyzed using an independent
Student’s t-test.
For the neuropathic pain experiments data are expressed as mean ± standard
error of the mean (s.e.m.) for visualization purposes only.To obtain a linear
scale of perceived intensity in the mechanical allodynia test the logarithm of
the withdrawal thresholds was plotted. For both cold and mechanical
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allodynia tests differences between baseline and post-injection values were
calculated for each animal at each time point.
Differences between drug treatment groups were analyzed using the
Kruskall-Wallis test because of the non-parametric nature of the data.When
appropriate, post hoc analysis was performed using the Mann-Whitney U
test, comparing each treatment dose with vehicle, and a Bonferroni-
correction was performed. Dose-response curves were generated for the
time of peak effect (30 min after injection).Therefore, post-injection values
were expressed as a percentage of baseline value and mean ± S.E.M. of these
percentages were plotted against the administered dose.
For all tests, a probability level of p≤0.05 was the criterion for a significant
difference.
Results
The aim of this study was to identify peptides which are selective for the
MC4R as compared to the other brain MCRs. In the first part of this study,
the heptapeptide [Nle4, Gly5, D-Phe7]-α-MSH(4-10), (compound E8, see
Table I) was mutated at several positions into different amino acids. The
analogues from this library (library I) were screened for affinity and activity on
the MC3R, MC4R and MC5R. In the second part of this study, the results
from library I were further explored with a new set of compounds (library II).
Library I 
The sequence of E8 was based on α-MSH(4-10) because this is the message
sequence of melanocortins, which contains the necessary information for
binding to melanocortin receptors [27,28]. Furthermore, replacing Met4 for
Nle4 increases stability and potency of the peptide [19,29], and Gly5 was
chosen because it was shown before to prevent loss of MC4R affinity due
to mutations elsewhere in the molecule, without having much effect by itself
[19]. Inserting a D-Phe at position 7 increases the potency of melanocortin
compounds [29]. E8 was not mutated at positions 7 and 9 because previous
studies have shown that mutations on these positions generally result in
almost complete loss of affinity and potency at all receptors [30,31].
Selective MC4R Peptides
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Table II summarizes the Ki and EC50 values of the compounds of library I for
the different receptors. Substituting Nle4 (number 4 refers to the relative
position in α-MSH) with the small residues Ala and Gly resulted in a decrease
in affinity and biological activity for all receptors, but this was most
pronounced on the MC5R (>100-fold decrease). Substitution of Nle4 with a
Lys, however, slightly increased affinity for the MC3R (4-fold) and MC4R (2-
fold), but resulted in a 4-fold decrease in MC5R affinity.
Replacing Gly5 with Ala and Lys resulted in higher affinity for all three
receptors, but this was most pronounced on the MC3R and MC5R (6-fold
and 3 to 13-fold increase, respectively). [Asn5]-E8 and [Arg5]-E8 both had
lower affinities for all receptors. In contrast to the binding data, the EC50 values
of [Asn5]-E8 and [Arg5]-E8 for all three receptors indicated increased activity.
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Ki and EC50 values of
compounds from
library I for the MC3R,
MC4R and MC5R.
Data represent EC50
and Ki values of single
experiments, in which
eleven concentrations
of compound were
tested in triplicate on
each receptor. In
every experiment, E8
(activation) or NDP-
MSH (binding) were
included as internal
controls. In case of
incomplete activation
curves, percentages
denote the activity
elicited by 1 µM of
compound relative to
maximal α-MSH
activity at that
receptor. “-“ indicates
no measurable
displacement at 1 µM.
Table II.
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For [Ala6]-E8 and [Phe6]-E8, a decrease in affinity for all three receptors was
observed, but these decreases were more pronounced on the MC3R and
MC5R (3- to 7-fold decrease). Affinity of [Lys6]-E8 for the MC4R was
slightly decreased, whereas for the MC3R and MC5R there was a 4- and 7-
fold decrease, respectively. In contrast, the biological activity of [Lys6]-E8 on
the MC5R was slightly increased.
Mutations on position 8 resulted in a relatively large decrease in affinity for
all receptors. [Ala8]-E8 showed the largest decreases in affinities as compared
to the reference peptide (less than micromolar affinities for the MC3R and
MC5R and 135-fold reduction for MC4R). [His8]-E8 and [Lys8]-E8 showed
similar binding profiles (12 to 16-fold decrease for MC3R and MC5R and
7 to 8-fold decrease for the MC4R).
Affinity of [Asp10]-E8 for the MC5R was greatly reduced compared to the
reference peptide. Also on the other receptors [Asp10]-E8 showed loss of
affinity, but this was only 6- (MC3R) and 7-fold (MC4R). [Ala10]-E8 and
[Lys10]-E8 showed only small decreases in affinity for all receptors.
Library II
In the second part of this study, new compounds were synthesized (library
II) with the intention of maintaining affinity for the MC4R while losing
affinity for the MC3R and MC5R. Because insertion of a Lys on position 6
61
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Table III.
Primary structures of compounds from library II. Underlined are the residues which are modified as
compared to JK1.
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gave the highest MC4R binding selectivity in library I (compound [Lys6]-
E8), this was chosen as the new starting point. The primary structures of
peptides from this new library are shown in Table III.
To allow better comparison, compounds [Lys6]-E8 and [Ala6]-E8 were re-
synthesized and included in library II (homologous of library II are named
JK1 and JK9, respectively). From Table IV it can be seen that the data of JK1
and JK9 are in agreement with the data of [Lys6]-E8 and [Ala6]-E8,
respectively (Table II). In the binding assay, JK1 has 90-fold MC3R/MC4R
and 114-fold MC5R/MC4R selectivity, and in the activation assay this was
8.5-fold and 30-fold, respectively. JK9 is less selective for the MC4R as
compared to JK1, mainly because of reduced affinity for the MC4R. In
contrast, JK9 was more MC4R-selective than JK1 in the activation assay.
The effect of substituting His6 with a Lys-residue was tested in truncated
peptides that consist of residues 6 to 9, the positions of the message sequence
of melanocortin peptides [32]. As can be seen in Table IV, the tetrapeptide
containing Lys6 (JK10) had reduced affinity for the MC3R (3-fold) and the
MC4R (4-fold) compared to the His6 containing analogue (JK44). Both
tetrapeptides had very low affinity for the MC5R (>10 µM).
In compound JK48, Lys6 is combined with a Gly on position 4, which in
library I lowered affinity for the MC5R. Compared to JK1, compound JK48
showed a 54-fold reduction in affinity for the MC4R, whereas at the MC3R
and MC5R there was only a 9 and 7-fold reduction, respectively. JK48 was
a full agonist on the MC3R and MC4R, but did not stimulate the MC5R
at concentrations up to 10 µM.
To investigate whether at position six a basic residue increased selectivity for
the MC4R, an Arg was inserted at this position (compound JK64).
Compared to JK1, JK64 showed increased affinity for all receptors. The
increase was most pronounced on the MC3R and MC5R (19 and 11-fold
for the MC3R and MC5R, vs. 6-fold increase for the MC4R).
Antagonists
A commonly used MC4R antagonist is SHU9119 [33] (Table I). The D-
Nal(2)7 of SHU9119 is the residue that confers the antagonistic activity for
the MC4R.At the MC3R and the MC5R, SHU9119 is a partial agonist and
a full agonist, respectively [33]. When D-Phe7 of JK1 was replaced by D-
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Nal(2)7 (compound JK7), a similar activation profile as SHU9119 was
obtained: partial agonism at the MC3R, antagonism at the MC4R and full
agonism at the MC5R (Table V). SHU9119 and JK7 have similar antagonist
potencies for the MC4R, but JK7 had higher MC4R selectivity than
SHU9119. In the binding assay, MC4R selectivity of JK7 was 34-fold and
112-fold as compared to the MC3R and MC5R, respectively.
JK49 contains a Gly on position 4, combined with D-Nal(2)7. Compared to
JK7, JK49 has reduced affinity for the MCRs (6-fold for the hMC3 and
MC4R and 23-fold for the MC5R). Surprisingly, JK49 is an antagonist for
the MC3R and shows partial agonism at the MC4R.
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Figure 1. Grooming
scores after i.c.v. injection
(black bars) of
compounds. [D-Tyr4]-MTII
and JK1 were also tested
after i.v. injection (grey
bars). Doses used are: 100
ng i.c.v. for all compounds
except JK48 (300 ng) and
100 µg for i.v. injections.
Bars indicate mean ±
s.e.m. of six rats (* p< 0.05
vs. saline).
Figure 2. Effect of i.c.v.
injections of compounds
on α-MSH (1.5 µg)-
induced grooming. Mixes
containing 1.5 µg α-MSH
and 500 ng of blocking
compound were used.
Bars indicate mean ±
s.e.m. of six rats (* p< 0.05
vs α-MSH).
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Effects on grooming behaviour
The compounds identified in this study were tested for in vivo activity in a
rat-grooming assay. It was shown before, that grooming behaviour induced
by application of MCR- agonists is mediated by the MC4R [34].
As can be seen in Figure 1, intracerebroventricular (i.c.v.) injections of JK1,
JK48 and JK64 induced grooming behaviour. For comparison, the grooming
data of [D-Tyr4]-MTII, a selective MC4R compound [34], are also included
in the figure.The order of potency in inducing grooming behaviour is the
same as the order of affinity of the compounds for the MC4R (JK64 > JK1
> [D-Tyr4]-MTII > JK48). I.v. injections (100 µg) of  [D-Tyr4]-MTII and
JK1 also induced grooming behaviour.
The MC4R antagonists SHU9119, JK7 and the weak partial agonist JK49
were tested for their ability to block α-MSH induced grooming (Figure 2).
All compounds at a dose of 500 ng were able to reduce the grooming
induced by 1.5 µg α-MSH, with JK7 having the strongest effect. I.v.
injections of JK7 (100 µg), applied immediately after i.c.v. injection of α-
MSH (1.5 µg), reduced the grooming score to 61% (± 4%) of animals that
received i.v. injections of saline after the α-MSH injections.
Selective MC4R Peptides
Figure 3. (A) The effect of intrathecally (i.t.) injected JK1 on withdrawal latencies to cold stimulation
(4.5 °C) in neuropathic rats. Differences between post-injection and baseline value are plotted. (B)
Dose-response curves of the effect of i.t. MTII, JK1 and [D-Tyr4]-MTII on withdrawal latencies to cold
stimulation (4.5 °C) in neuropathic rats. Values represent latencies at 30 min post-injection as a
percentage of baseline. Data of MTII and [D-Tyr4]-MTII are from [25].
Data are presented as mean ± s.e.m. of 10 rats each (* p<0.05 vs. vehicle)
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Effects on cold and mechanical allodynia 
None of the melanocortin compounds tested had any effect on cold or
mechanical withdrawal thresholds in control animals (data not shown).
In CCI animals mean baseline withdrawal latency at 4.5°C was 6.05 ± 0.35
s.This was significantly lower than in control animals (9.86 ± 0.06 s, data not
shown), thus indicating a cold allodynia. Intrathecal (i.t.) administration of
JK1 (150, 500 and 1500 ng) to CCI animals produced a dose-dependent
decrease in withdrawal latencies to cold stimulation (Fig. 3A). Peak effects
were seen at 30 minutes after injection, at which time withdrawal latencies
were reduced to 9.8 ± 3.5% of baseline at the highest dose tested. The
potency of JK1 for increasing cold allodynia was intermediate to the
potencies of MTII and [D-Tyr4]-MTII (Figure 3B).
The mean baseline mechanical withdrawal threshold in CCI animals was
also significantly lower than in controls (5.32 ± 0.21 g and 21.09 ± 0 g
respectively, data not shown), demonstrating that CCI animals also developed
a mechanical allodynia.As for the cold stimulation test, administration of JK1
dose-dependently decreased mechanical withdrawal thresholds. With the
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Figure 4. (A) The effect of intrathecally (i.t.) injected JK1 on withdrawal thresholds to mechanical
stimulation (von Frey filaments) in neuropathic rats.Thresholds are transformed to the logarithm of
the applied force. Differences between post-injection and baseline value are plotted. (B) Dose-
response curves of the effect of i.t. MTII, JK1 and [D-Tyr4]-MTII (DTyrMTII) on withdrawal thresholds
to mechanical stimulation in neuropathic rats.Values represent thresholds at 30 min post-injection as
a percentage of baseline. Data of MTII and [D-Tyr4]-MTII are from [25].
Data are presented as mean ± s.e.m. of 10 rats each (* p<0.05 vs. vehicle).
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highest dose tested, 30 min. after injection responses were decreased to 18.7
± 7.4% of baseline (Figure 4A). The potency of JK1 for increasing
mechanical allodynia was inbetween those of MTII and [D-Tyr4]-MTII
(Figure 4B).
Discussion
In this study, the MC4R-selective agonist JK1 and antagonist JK7 were
identified. JK1 is an agonist for the MC4R with 90 and 110-fold selectivity
for the MC4R over the MC3R and MC5R respectively, as measured by
displacement of [125I]-[Nle4, D-Phe7]-MSH. JK1 is more selective for the
MC4R than our previously described [D-Tyr4]-MTII [34]. It has similar
MC4R/MC3R selectivity as the previously described compound
cyclo(NH-CH2-CH2-CO-His-D-Phe-Arg-Trp-Glu)-NH2 [35], but
MC4R/MC5R selectivity of this latter compound was higher (>1000). JK1
contains a Lys substitution of the His6 residue.This led to decreased affinity
for all MCRs, which was less pronounced on the MC4R. In general
mutations on position 6 affected binding to the MC3R and MC5R more
than the MC4R.Apparently the requirements for which residue is placed on
position 6 are less strict for the MC4R as for the MC3R and MC5R, which
in some cases is favourable for MC4R selectivity. In literature, there is
controversy about the importance of the His6 residue. Although His6 was
shown to be important for binding to the MC1R [30,36], different studies
describe contradicting results for other MCRs. For instance, some papers
describe that for binding to the MC4R the His6 is not important [31,36-38],
whereas others report that mutations on this position affect receptor activity
but not binding [32] or that they affect binding rather than activity [30].
Also, a recently published paper by Lee et al. [39] reports increased selectivity
for the MC4R over the MC3R by mutations on position 6. In these papers
however, a different context (e.g. α-MSH or MTII) was used in which the
role of His6 was explored, showing that surrounding residues influence the
effect of a mutation. In line with this, we found that when residues 4,5 and
10 were not present, as in compound JK10, insertion of a Lys on position 6
did not increase, though rather decreased MC4R selectivity. Similarly,
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substitution of Nle4 with a Gly in compound E8 decreased MC5R affinity
much more than when this substitution was applied to JK48.Thus, in our
studies, the effect of Gly4 depends on which residue is present on position
6. It had been noted before that at the Nle position of MTII (which is
analogous to position 4 in α-MSH) long and hydrophobic side-chains
increase potency at the MC5R [38,40]. The data described above support
our previous conclusion that residues outside the message sequence
influence the conformation of this message sequence, and in this way
influence potency and selectivity for the melanocortin receptor subtypes
[19].
Since substitution of the weak basic residue His6 with the more basic lysine
resulted in increased MC4R selectivity, we tested whether an arginine,
which is even more basic, at this position also would increase selectivity.This
substitution (JK64) considerably increased affinity for all receptors, but
MC4R-selectivity was decreased. Interestingly, it has been reported for
agouti protein that basic residues on position 116, which is thought to be
analogous to His6 in melanocortins, also increase MC4R binding [41].This
may indicate a possible similarity between MCR binding requirements for
MSH-based ligands and agouti protein. In line with this, we have shown
before that one residue of the MC4R is important for both agouti protein
binding as well as MSH –based compounds [19,42].
In JK7, a D-Nal(2) is inserted at position 7. In SHU9119 [33], the D-Nal(2)7
determines the antagonism of this compound at the MC3R and MC4R.
This effect of D-Nal(2)7 was also seen by others [43]. Therefore, it was
expected that JK7 would be an antagonist for the hMC4R.Table V shows
that JK7 indeed is antagonist for the MC4R, but with greater MC4R-
selectivity than SHU9119. However, based on Ki values, JK7 is less MC4R-
selective than the recently discovered antagonists HS028 [44] and MBP10
[45], which had 80-fold and 125-fold MC4R/MC3R  selectivity,
respectively. Our data also show that, like for cyclic peptides [33,43],
insertion of D-Nal(2)7 also results in MC4R antagonism in linear peptides.
We started this study by screening a small library of peptides produced by
the PEPSCAN method. This method is suitable for rapid production of a
large amount of compounds with point mutations in a certain peptide
sequence. Our data show that the PEPSCAN compounds are suitable for use
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in MCR selectivity screening. Moreover, this strategy allowed us to identify
selective MC4R compounds. Therefore, this method seems very useful in
rapid testing large libraries of mutated compounds on MCRs, but probably
also other receptors.The screening also provided structure-activity relations
that may be useful in further development of selective MCR compounds.
For instance, compounds with substituted Arg8 all had decreased affinity for
all three MCRs.Apparently, the requirements at this position for binding and
activation are strict.This is in agreement with other studies, where mutations
at this position greatly reduced affinity for MCRs [30,38,46,47]. Arg8 was
substituted by a negatively charged residue (Asp), a positively charged residue
(Lys) and by the uncharged Ala. However, all these residues have shorter side
chains than Arg, suggesting that the length of the residue at this position may
play a role in affinity and activity. Mutations on position 5 led to diverse
effects on the MCRs. Notably, the MC3R and MC5R responded similarly
to mutations on position 5. It has been noted before that the MC3R and
MC5R form a subclass within the MCR family with similar SAR [40].
For most ligands, changes in activity as compared to the reference peptide
correlated with the binding data. Still, for some ligands discrepancies
between affinity and biological activity were found. For instance, [Asn5]-E8
and [Arg5]-E8 showed decreased affinity but increased biological activity for
all receptors. Discrepancies between binding and activation data of
melanocortin ligands have been described before [30,32,48]. One
explanation may be that affinity was measured by heterologous displacement
of radioligand.The ligands may still bind to the receptor with high affinity,
though be poor competitors for the radioligand, resulting in an
underestimation of the affinity of the ligand for the receptor.This has been
described for the NK-1 receptor, which binds septide and neurokinin A
with high affinity, although high concentrations of these ligands are needed
to displace the NK-1 radioligand substance P [49].
The compounds identified in this study show activity in vivo. All MC4-
agonists tested were able to induce grooming and the MC4-antagonists
blocked α-MSH-induced grooming. Previously, we used the selective
compound [D-Tyr4]-MTII to show that melanocortins induce grooming in
the rat via the MC4R [34]. Here, we extend these results by showing that
the more MC4R-selective compound JK1 also induces grooming. The
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potency of the compounds in inducing grooming or blocking α-MSH-
induced grooming correlated with the binding data of these ligands for the
MC4R, although it can not be excluded that the lower blocking potency of
JK49 is due to the partial agonism of this compound at the MC4R.
Apparently, the in vivo potencies are mainly determined by the
pharmacodynamic properties of the compounds for the MC4R, suggesting
that their pharmacokinetic properties are similar. Therefore, these
compounds seem suitable for use in further in vivo research on the roles of
the MCR subtypes in physiological processes.
JK1 and JK7 were also tested for their ability to pass the blood-brain barrier
by evaluating the effects of i.v. injections of these compounds on grooming
behaviour, which is a measure of central MC4R activation.The data suggest
that JK1 and JK7 are able to pass the blood-brain barrier, since i.v. injections
of JK1 induced grooming and i.v. applied JK7 blocked centrally applied α-
MSH shortly after injection.
Recently it has been demonstrated that melanocortin compounds affect cold
and mechanical allodynia in rats with a chronic constriction injury (CCI),
which induces neuropathic pain, and that these effects are most likely
mediated via the MC4R [25]. Therefore, JK1 was also tested in CCI rats.
Indeed, JK1 increased both cold and mechanical allodynia, with potencies
inbetween those of MTII and [D-Tyr4]-MTII. These data support the
involvement of the MC4R in these processes.
In conclusion, we have identified a selective MC4R agonist and antagonist.
The compounds were identified using a library generated by the PEPSCAN
method.This method thus proves to be useful in analysing point mutations
in a reference peptide, in this case with a melanocortin-based sequence.The
activity of JK1 in a model for neuropathic pain strengthens the involvement
of the MC4R in modulating this process.The compounds identified will aid
further research on identifying the exact roles of the different melanocortin
receptors.
Chapter 2
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Abstract
Melanocortin ligands accelerate functional recovery after peripheral nerve crush. It is not
known what mechanism is involved or via which melanocortin receptor this effect occurs,
albeit indirect evidence favours the melanocortin-4 receptor. To test whether the
melanocortin-4 receptor (MC4R) is involved in the effects of melanocortins on functional
recovery, we used melanocortin compounds that distinguish the MC4R from the MC1R,
MC3R and MC5R on basis of selectivity and agonist /antagonist profile. Activation and
binding studies showed that the previously described MC4R-selective peptides JK1 and [D-
Tyr4]-MTII are also potent on the MC1R. Both peptides did not accelerate sensory
recovery in rats with a sciatic nerve crush, whereas the non-selective melanocortin agonist
MTII was effective. The MC3R/MC4R antagonist SHU9119 also enhanced sensory
recovery.This effect seemed not due to interaction with the MC4R, since another MC4R
antagonist JK46, which has more selectivity, was ineffective.Together, these data suggest that
melanocortins do not accelerate sensory recovery via interaction with the MC4R.
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Introduction
It is well known that melanocortins (e.g. ACTH and α-MSH) can stimulate
nerve regeneration after axonal injury. In 1980, Strand et al. [1] were the first to
describe that ACTH enhances sensorimotor recovery after sciatic nerve crush.
Further studies showed that this neurotrophic property of α-MSH and other
compounds is contained in the melanotropic moiety (ACTH(4-10)) of these
compounds [2,3]. The enhanced functional recovery is accompanied by
increased numbers of motor endplates [1] and myelin-positive sprouts [4]. Both
place and timing of peptide administration are important: the effects were
augmented when peptides were applied soon after injury or near the lesion site
[5,6].
The exact mechanisms via which the melanocortins exert their neurotrophic
effects are unknown, although many possibilities have been investigated. First,
melanocortins could act directly on the regenerating nerve cells. Indeed,
melanocortins increase neurite outgrowth in cultured dorsal-root ganglion
(DRG) neurons [7,8] and in spinal cord-slices [9]. Second, the effects could be
via the neuro-supporting glial cells. Astrocytes [10]respond to melanocortins
and the potent [Nle4- D-Phe7]-α-MSH  binds to a protein expressed by
Schwann cells [11], indicating that these cells may facilitate the neurotrophic
effects of these ligands. Especially Schwann cells play an important role in
peripheral nerve regeneration [12] and are therefore good candidates. Third,
since the immune system plays an important role in the first phase after nerve
injury, the Wallerian degeneration [12,13], the neurotrophic effects of
melanocortins may be mediated by immune cells. In particular macrophages
are important in this process.The anti-inflammatory effects of melanocortins
on the immune system are well described [14,15], and the MC1R and MC5R
are expressed on monocytes and lymphocytes, respectively [15-18]. However,
no direct role for immunomodulation by melanocortins in nerve regeneration
has been established. A fourth option is that at least for sensory recovery,
melanocortins may influence central neuronal networks, for instance in the
spinal cord [19]. The adapted network could become more efficient in
conducting signals, resulting in a better performance in recovery tests.
Knowing which melanocortin receptor (MCR) subtype(s) mediate(s) the
enhancing effects of melanocortin ligands would certainly advance the
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elucidation of the mechanism of the stimulating effects of melanocortins on
recovery. Lack of selective melanocortin compounds has hampered
identification of the melanocortin receptor subtypes that play a role. Until now,
five MCR subtypes have been cloned, which were named MC1R to MC5R
[20-27]. The MC2R is not a likely candidate, since α-MSH is effective in
regeneration while it does not activate the MC2R [28,29]. Conversely, γ-MSH
is ineffective in nerve regeneration, but is a good MC3R ligand, pleading
against a role for the MC3R.This leaves the MC1R, MC4R and MC5R as
the putative MCRs involved in nerve regeneration.The MC4R and MC5R
are both expressed in neuronal tissue, but the MC4R is the only MCR found
in neuronal tissue outside the brain. Also, melanocortins stimulate neurite
outgrowth in Neuro 2A cells via endogenously expressed MC4Rs [30],
providing evidence for a direct role for the MC4R in enhancing neuronal
growth. Therefore, the MC4R is considered the most likely candidate for
mediating the neurotrophic effects of melanocortins. Recently, the potent
melanocortin analogue MTII (Ac- Nle4-c[Asp5, D-Phe7, Lys10]-α-MSH(4-10)-
NH2) was shown to be very effective in enhancing sensory recovery after sciatic
nerve crush in the rat, and it was protective in cisplatin-induced neuropathy
[31]. This underlined the importance of the melanocortin system in nerve
regeneration and protection. However, since MTII only possesses moderate
selectivity for the MC4R and MC1R over the MC3R and MC5R [32], no
conclusion could be drawn about involvement of the MC4R in these processes.
Therefore, the present study was set up to further investigate the role of the
MC4R in sensory recovery. The MC4R-selective agonists JK1 [33] and [D-
Tyr4]-MTII, the non-selective MC4R antagonist SHU9119 [34], and the
MC4R selective antagonist JK46 were tested in a model for sensory recovery
after sciatic nerve crush in the rat.
Materials and Methods
Peptides
NDP-MSH  ([Nle4, D-Phe7]-α-MSH), SHU9119 (Ac-Nle4-c[Asp5, D-
Nal(2)7, Lys10]α-MSH(4¯10)-NH2) and MTII (Ac-Nle
4-c[Asp5, D-Phe7,
Lys10]α-MSH(4¯10)-NH2) were purchased from Bachem (Bubendorf,
Chapter 3
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Switzerland). JK46 and JK1 were synthesized on an automatic ABI 433A
Peptide Synthesizer using FastMoc 0.25 mmol chemistry as described
previously [33]. [D-Tyr4]-MTII was synthesized using Fmoc solid phase
synthesis as reported elsewhere [35].
Cell culture and transfection
Human embryonal kidney (HEK) 293 cells were grown in Dulbecco’s
Modified Eagle Medium DMEM (Gibco, Paisley, Scotland) supplemented
with 10% fetal calf serum (Integro, Zaandam, the Netherlands), 2 mM
glutamine (Gibco, Paisley, Scotland) and non-essential aminoacids (NEAA,
Gibco, Paisley, Scotland). DNA was transfected into cells with a standard
calciumphosphate precipitation protocol. Receptor cDNAs of the rat
melanocortin-3 receptor (rMC3R), rMC4R, rMC5R and mouse MC1R ,
each cloned in the vector pcDNA3 (Invitrogen, Carlsbad, CA) were used.
The CRE-LacZ reporter gene construct as described by Chen et al.[36] was
used to measure receptor activation.
Binding assay
IC50 values were determined by displacement of 125I-NDP-MSH. Iodinated
NDP-MSH was produced using bovine lacto-peroxidase (Calbiochem, La
Jolla, CA) and 125I-Na (ICN,Aurora, OH) according to Oosterom et al. [37]
and subsequently high pressure liquid chromatography-purified on a C18
column (µBondapak 3.9 X 300 mm,Waters, Milford, MA).
Cells growing in 24-wells plates were washed with tris-buffered saline (TBS)
(saline 0,14 M, Tris 25 mM, potassium chloride 5 mM, pH 7.4)
supplemented with 2.5 mM calcium chloride and incubated for 30 min at
room temperature with peptides and tracer diluted in Ham’s F10 medium
(Gibco, Paisley, Scotland) supplemented with 2.5 mM calcium chloride,
0.25% bovine serum albumine (BSA) (ICN,Aurora, USA) and 200 KIU/ml
aprotinin (Sigma, Steinheim, Germany).After two washes with ice-cold TBS
(+ 2.5 mM calcium chloride) to remove non-bound tracer, the cells were
lysed in 1M sodium hydroxide and samples were counted in a γ-counter.
Activation assay
HEK293 cells growing in 10-cm dishes were co-transfected with 100-200
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ng receptor DNA and 7 µg of CRE-LacZ construct [36].After transfection,
the cells were plated into 96-wells plates (BectonDickinson).Two days after
plating, the cells were incubated with peptides at the appropriate
concentrations in serum-free medium (DMEM containing 0.2% BSA (ICN,
Aurora, USA), glutamine (Gibco, Paisley, Scotland) and non-essential
aminoacids (Gibco, Paisley, Scotland) according to manufacturers
instruction). After 5-6 hours of incubation, the assay medium was aspirated
and 40 µl of lysis mix (PBS containing 0.1% triton-X-100 (Boehringer,
Mannheim, Germany)) was added.The plates were stored at -20°C and after
thawing 80 µl of substrate mix (0,1 M phosphate buffer, pH 7.4 containing
1.6 g/l o-Nitrophenyl β-D-galactopyranoside (ONPG, Molecular probes,
Leiden, the Netherlands), 67.5 mM β-mercaptoethanol (Merck, Darmstadt,
Germany) and 1.5 mM magnesium chloride) was added.Absorbance at 405
nm was determined in a Victor2 microplate reader (PerkinElmer, Brussels,
Belgium).
Animals
Male Wistar rats, 6-7 weeks old and weighing 130-150 g at the start of the
study were used.Animals were housed in groups of 2-3 in plastic cages on a
sawdust bedding and kept at a 12/12hr light/dark cycle, with food and water
available ad libitum. All testing procedures in this experiment were approved
of by the Ethics Committee on Animal Experiments of the Utrecht
University.
Surgery and sciatic nerve crush
Rats were anaesthetized by subcutaneous injection of 0,8 ml/kg Hypnorm
(Janssen Pharmaceuticals, Grove, Oxford). Sciatic nerve crush was performed
as described previously [38]. Briefly, an incision over the length of the right
hip was made, and after exposing the sciatic nerve, a haemostatic forceps was
used for exactly 30 seconds to induce crush injury of the sciatic nerve.
Drug administration and functional recovery
In the first experiment, 48 rats were randomly divided into four groups of
twelve animals.The animals received every 48 hours subcutaneous injections
of  MTII (20 µg/kg), [D-Tyr4]-MTII (20 µg/kg), SHU9119 (20 µg/kg) or
Chapter 3
80
proefschrift wouter  04-02-2003  16:24  Pagina 80
saline. In the second experiment, four treatment groups of twelve animals
each received JK46  (20 µg/kg), JK1 (20 µg/kg), JK1 (100 µg/kg) or saline.
Treatment started immediately after nerve crush, and was continued
throughout the whole experiment.The MTII treated animals and the saline
controls of the first experiment were tested daily for recovery, starting at day
12 post operation, until day 25 post operation.The remaining groups were
tested only on day 19.
Sensory recovery was measured with the foot reflex withdrawal test [38]. In
this test, a small electrical current ranging from 0.1-0.6 mA, is applied with
steps of 0.1 mA to determine at what level sensory function is regained.
Non-lesioned rats will retract the stimulated paw already at 0.1 mA, whereas
lesioned rats will not respond even to 0.6 mA shortly after surgery.Thus, if
rats responded already at 0.1 mA, functionality was defined as 100%, whereas
if the rat did not respond even to 0.6 mA, recovery was scored as 0%. Per
rat, the lowest current at which a reaction is observed represents the level of
functional sensoric recovery (0.1 mA = 100%; 0.2 mA = 84%; 0.3 mA =
67%; 0.4 mA = 50%; 0.5 mA = 34%; 0.6 mA = 17%; >0.6 mA = 0%).
Statistical analysis
IC50 and EC50 values were calculated with non-linear regression using Prism
software (GraphPad, San Diego, USA). Averages of multiple (3–5)
independent experiments were calculated for each peptide-receptor
combination. For recovery, differences between drug treatment groups at day
19 were first analysed using the Kruskall-Wallis test because of the non-
parametric nature of the data. Each group was then compared with the saline
controls with the Mann-Whitney U test. A probability level of 5`% was
considered significant.
Results
Five melanocortin analogues were tested for their effects on sensory
recovery after sciatic nerve crush.The primary structures of these peptides
are shown in Table I. First, IC50 and EC50 values of the peptides were
determined for the rat MC3R, MC4R MC5R and mouse MC1R (Table
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II). MTII had no considerable selectivity for any of the receptor subtypes,
although the affinity for the MC5R was lower compared to the other
receptor subtypes. [D-Tyr4]-MTII was selective for the MC4R as compared
to the MC3R and MC5R (15-fold lower affinity for the MC3R and 200-
fold lower affinity for the MC5R), but possessed even higher affinity and
potency for the MC1R. Like [D-Tyr4]-MTII, JK1 is selective for the MC4R
as compared to the MC3R and MC5R (47-fold and 180-fold selectivity,
respectively), but also has high affinity and potency for the MC1R. JK1 had
higher affinity and potency at all receptors, as  compared to [D-Tyr4]-MTII.
In agreement with previous studies [39,40], SHU9119 was non-selective,
with an antagonistic profile for the MC3R and MC4R, and full agonist
activity at the MC1R and MC5R.We also tested the new MC4R selective
compound JK46. Similar to SHU9119, JK46 has an antagonistic profile at
the MC3R and MC4R and an agonistic profile at the MC1R and MC5R.
In a previous study, the effective dose of MTII for sensory recovery was
found to be 20 µg/kg [31], and this dose was therefore also used in the
present study.Application of MTII at this dose accelerated sensory recovery
in animals bearing a sciatic nerve crush (Figure 1), confirming previous
results [31]. Recovery reached about 50% at day 19 for MTII treated
animals.Therefore, recovery was measured at this day to compare the effects
of JK1, [D-Tyr4]-MTII, SHU9119 and JK46 on sensory recovery to that of
Chapter 3
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Alignment of the peptides that were used in the sciatic crush model, to α-MSH and NDP-MSH.
Numbering according to relative position in α-MSH. Note that in [D-Tyr4]-MTII, it is the D-Phe
residue of MTII (which aligns to position 7 of α-MSH) that is replaced by a D-Tyr residue.
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Table II.
Figure 2. Effects of peptides on sensory
recovery after sciatic nerve crush. Recovery
was measured with the foot reflex
withdrawal test at day 19 after crush lesion.
The mean percentage of recovery (MPR)
was calculated for each group, and
subsequently the MPR of saline treated
animals was subtracted from the MPR of
animals that received peptide to calculate
percentage recovery above saline controls.
Error bars indicate s.e.m. , and are given for
visualization purposes only. “*”, significantly
different (p < 0.05) from saline controls
(Kruskall-Wallis test, followed by a Mann-
Whitney U test).
Figure 1. The effect of subcutaneous
injections of MTII on sensory recovery after
sciatic nerve crush.Animals received either 20
µg/kg MTII or saline every 48 hours. Recovery
was measured daily with the foot reflex
withdrawal test.
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MTII. Analogous to van der Zee et al. [41], these data are expressed as the
percentage recovery of MTII-treated animals above control, as depicted in
Fig. 2. At the same dose as MTII, both JK1 and [D-Tyr4]-MTII did not
accelerate sensory recovery compared to saline controls. JK1 was also
ineffective at a higher dose (100 µg/kg). Unexpectedly, the MC3R/MC4R
antagonist SHU9119 enhanced recovery. JK46 on the other hand, was
ineffective.
Discussion
Based on the available data, the MC4R was always considered the best
candidate to mediate the effects of exogenously applied melanocortins on
nerve regeneration. However, the results described in this study suggest that
the MC4R is not involved.
The effects of the peptides on functional recovery did not correlate with
their pharmacological profile for the MC4R.The MC4R selective agonists
JK1 and [D-Tyr4]-MTII did not enhance sensory recovery after sciatic nerve
crush, while the non-selective agonist MTII was effective at the same dose.
JK1 was also ineffective at a higher dose, indicating that the lack of effect of
JK1 is not due to lower potency at the MC4R, as compared to MTII. It is
also unlikely that JK1 and [D-Tyr4]-MTII were ineffective due to lack of in
vivo efficacy at the MC4R. Previously we have shown that
intracerebroventricular (i.c.v.) applied JK1 and [D-Tyr4]-MTII induce
grooming, which is a MC4R mediated behavioral response [42], and
intrathecal injections modulated neuropathic pain [33,43]. Moreover, i.v.
applied JK1 was also able to induce grooming behaviour. Although a
different delivery route was used in the present study, these data show that
JK1 and [D-Tyr4]-MTII are effective at the MC4R in vivo.
Involvement of the MC4R was also investigated with antagonists. If the
neurotrophic effects of melanocortin agonists are mediated by the MC4R,
antagonists for this receptor should not enhance recovery. Rather, inhibition
of recovery would be expected if endogenous melanocortins influence
sensory recovery via the MC4R. Indeed, a MC4R antagonist inhibited α-
MSH induced neurite outgrowth in Neuro 2A cells in vitro [30]. The
Chapter 3
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stimulatory effect of the MC4R antagonist SHU9119 in the present in vivo
study thus questions the putative role of this receptor in sensory recovery.
Moreover, JK46, which is also an antagonist at the MC4R with similar
affinity as SHU9119, was ineffective. Thus, JK46 and SHU9119 are two
compounds with a similar pharmacology for the MC4R, but show different
effects on sensory recovery.
Taken together, the data argue against a role for the MC4R in the
acceleration of sensory recovery by administered melanocortins.This seems
in contradiction with a previous report [30], where neurite outgrowth by
Neuro 2A cells was stimulated in vitro via endogenously expressed MC4Rs.
Though, it should be noted that these in vitro findings may not represent a
mechanism that is actually involved in functional recovery in vivo. One other
argument that has been put forward to implicate the MC4R in functional
recovery, is the presence of MC4Rs in the spinal cord [19]. Based on our
results, these spinal cord MC4Rs thus seem not to enhance sensory recovery
after sciatic nerve crush. In the present study, however, only sensory recovery
was measured, whereas melanocortin ligands show neurotrophic effects in
other processes as well. There may still be a role for (spinal) MC4Rs for
instance in neural development [44-47] and motoric recovery (for
references, see [8]). On the other hand, it was already noted before that the
exact localization of the MC4R within the spinal cord favored a role in
nociception rather than in recovery. In fact, these receptors were recently
shown to modulate neuropathic pain [43], which may represent their main
function.
Of the other three receptor subtypes that were pharmacologically tested in
this study, the MC1R and MC3R are also not likely candidates. Like for the
MC4R, JK1 is a potent agonist for the MC1R, and the lack of effect of JK1
at the two tested doses also argues against involvement of the MC1R in
accelerating sensory recovery. SHU9119 is an antagonist also for the MC3R,
and would be expected to have no effect by itself if the MC3R is the
mediator of the effects of melanocortin agonists.Thus, as for the MC4R, the
positive effect of SHU9119 on sensory recovery pleads against a role for the
MC3R.
With the pharmacological profiles of the peptides used in this study we can
not exclude a role for the MC5R.The enhancing effect of SHU9119 could
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be explained by its agonistic profile and high affinity for the MC5R.
Conversely, the low potency of JK1 and [D-Tyr4]-MTII and the low affinity
of JK46 for the MC5R could explain the lack of effects of these peptides. If
the MC5R was involved, what would be the mechanism? The important
role of the immune system in nerve regeneration and the expression of the
MC5R in the spleen and by lymphocytes [18,25,48] tempts to speculate a
role for the immune system. In line with this, melanocortins seem to act at
the crush site [6], which is also the site of action of immune cells.The anti-
inflammatory effects of melanocortins are well known [14], and therefore
melanocortins could well diminish the inflammatory responses following
nerve injury. It is known that the immune system can induce secondary
damage beyond the lesion itself [49] and reducing this secondary damage
would advance recovery. However, more proof is needed to conclude that
the MC5R is the receptor that mediates the enhancing effects of
melanocortins on functional recovery. In addition, it should be noted that
involvement of another, yet undefined receptor has been suggested. This
comes from the observation that the melanocortin analogue ORG2766
clearly has neurotrophic effects [2,50], but it does not bind to melanocortin
receptors [24,51]. Thus, interaction of  MTII and SHU9119 with this
putative, unknown receptor also may facilitate the enhancing properties of
these compounds.
In conclusion, we tested whether the MC4R plays a role in acceleration of
sensory recovery after sciatic nerve crush by use of several melanocortin
ligands. Our results suggest that the MC4R is not involved in the stimulating
effects of melanocortins on sensory recovery, since the effects of the ligands
does not correspond with their MC4R pharmacology. It remains to be
investigated which receptor subtype is involved, but based on this study the
MC5R is an interesting candidate.
Chapter 3
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Abstract
The central melanocortin system has been demonstrated to act downstream of leptin in
the regulation of body weight. The system comprises α-MSH, which acts as agonist, and
agouti-related protein (AgRP), which acts as antagonist at the melanocortin (MC)3 and
MC4 receptors (R).This property suggests that MCR activity is tightly regulated and that
opposing signals are integrated at the receptor level. We here propose another level of
regulation within the melanocortin system by showing that the human(h)MC4R displays
constitutive activity in vitro as assayed by adenylyl cyclase (AC) activity. Furthermore, human
AgRP(83-132) acts as an inverse agonist for the hMC4R since it was able to suppress
constitutive activity of the hMC4R both in intact B16/G4F melanoma cells and membrane
preparations. The effect of AgRP(83-132) on the hMC4R was blocked by the MC4R
antagonist SHU9119. Also the hMC3R and the mouse(m)MC5R were shown to be
constitutively active. AgRP(83-132) acted as an inverse agonist on the hMC3R but not on
the mMC5R. Thus, AgRP is able to regulate MCR activity independent of α-MSH. These
findings form a basis to further investigate the relevance of constitutive activity of the
MC4R and of inverse agonism of AgRP for the regulation of body weight.
Chapter 4
92
proefschrift wouter  04-02-2003  16:24  Pagina 92
Introduction
Melanocortin receptors (MCRs) are G-protein coupled receptors (GPCRs)
which are positively coupled to the cAMP pathway. Of the five MCRs that
have been cloned the MC1R is expressed on melanocytes in the skin where
it is involved in regulation of pigmentation.The MC4R is expressed in the
brain where it was shown to be involved in regulating metabolism and food-
intake both in rodents [1-4] and humans [5,6].The MC3R is expressed in
the brain, placenta and gut.The exact role of the MC3R is still unclear, but
it has been proposed that in the brain the MC3R could have a regulatory
role in metabolism and food intake upstream of the MC4R [7].
Besides the melanocortins (e.g. ACTH, α, - and γ-MSH), which act as
agonists on MCRs, endogenous high affinity peptide ligands for MCRs have
been found that act as antagonists, namely Agouti protein (Agouti) [8-10]
and Agouti-Related Protein (AgRP) [11,12]. The existence of different
ligands with opposing actions on the same receptor provides a mechanism
to tightly regulate MCR activity and to integrate opposing signals at the
receptor level.
Agouti is a paracrine factor expressed in dermal papilla in the hair follicle
where it regulates the switch from eumelanin to phaeomelanin synthesis by
melanocytes in mice [13]. In vitro,Agouti is an antagonist for the MC1R and
MC4R [10] and it has been suggested that Agouti regulates pigmentation by
blocking α-MSH binding to the MC1R [14]. However, several effects of
Agouti can not be explained by competition with α-MSH only. For
instance, it has been reported that incubation of cells expressing the MC1R
with Agouti in the absence of α-MSH resulted in lower cAMP formation
[15,16], decreased melanogenesis [16-18] and cell growth [19] and lower
tyrosinase expression [16]. Furthermore, Agouti can inhibit the response to
cholera toxin [17,20].These effects could be explained by inverse agonism
of Agouti.
AgRP, which shares sequence homology with Agouti, is expressed in the
arcuate nucleus of the hypothalamus, subthalamic nucleus and the adrenal
gland [11] and is a potent antagonist for the MC3R and MC4R, and a weak
antagonist for the MC5R [12,21,22]. Considerable evidence exists
suggesting that AgRP is involved in body weight regulation [11,12,23,24] by
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acting downstream of the adipose tissue derived satiety factor leptin [25,26].
AgRP reduces the maximal response of the human-MC4R (hMC4R) to α-
MSH, and evidence was provided that AgRP reduces activation of the
cAMP pathway in the absence of agonist, as assayed by measurement of
cAMP levels and reporter gene activity [12,27].
Understanding the mechanisms by which melanocortin ligands regulate
their receptors is essential for unraveling the physiological role of the
melanocortin system.Therefore, we tested directly whether the human (h)-
MC4R displays constitutive activity and whether AgRP is able to suppress
this constitutive activity. We used synthetic AgRP(83-132) [28] and
B16/G4F [29] cell lines stably expressing different levels of the hMC4R and
assayed for adenylyl cyclase activity.
Materials and methods
Chemicals and ligands
Forskolin was purchased from Sigma (Steinheim, Germany) and synthetic
human AgRP(83-132) was obtained from Phoenix Pharmaceuticals, Inc
(Mountain view, CA). α-MSH and [Nle4,D-Phe7]-α-MSH (NDP-MSH)
were purchased from Bachem (Bubendorf, Switzerland). SHU9119 was
synthesized as described previously [30].
Generation of cell lines
B16/G4F cells [29] were grown in RPMI1640 medium (Gibco, Paisley,
Scotland) supplemented with 10% fetal calf serum (Integro, Zaandam,
Netherlands) and 15 mM sodium hydrogen carbonate (NaHCO3). Cells
were transfected with hMC3R [31], hMC4R [32] or mMC5R [33] cDNA
cloned into pcDNA3 (Invitrogen, Carlsbad, CA) using calcium phosphate
precipitation. Clones, stably expressing MCRs were selected in medium
containing the neomycin analogue G418 (800 µg/ml, Gibco, Paisley,
Scotland).
Adenylyl cyclase activity
Adenylyl cyclase activity was determined using a modified method of Salomon [34].
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1. Intact-cell assay
Cells were grown in 24-well plates and incubated for two hours with
2µCi/ml [3,8-3H]-adenine (21.7 Ci/mmol, NEN, Boston, NA) in
Dulbecco’s modified Eagle’s medium (Gibco, Paisley, Scotland) containing
0.2% bovine serum albumine (BSA, CN, Aurora, OH), 2 mM L-glutamine
(Gibco, Paisley, Scotland) and non-essential amino acids. Subsequently, the
cells were washed with phosphate buffered saline (PBS, Gibco, Paisley,
Scotland) containing 0.25 mM isobutylmethylxanthine (IBMX, Sigma,
Steinheim, Germany) (PBS/IBMX) and incubated for 20 min with
compounds diluted in PBS/IBMX. Then 1 ml of cold stop solution (5%
trichloric acid (Merck), 1 mM cAMP (Boehringer, Mannheim, Germany), 1
mM ATP (Boehringer, Mannheim, Germany)) per well was added and the
plates were centrifuged at 250g. Finally, ATP and cAMP fractions were
separated on dowex (AG-50W-X4, Bio-Rad, Hercules, CA), respectively
alumina (WN-3, Sigma, Steinheim, Germany) columns. ATP and cAMP
fractions were dissolved in scintillation cocktail (Ultima Gold, Packard,
Meriden, CT)) and counted in a β-counter.
AC activity was calculated as the percentage of [3H]-ATP that is converted
to [3H]-cAMP using the equation [3H]-cAMP/([3H]-cAMP + [3H]-ATP). In
a typical experiment, from one well containing ~ 2·105 cells, 1.2 pmoles
(equivalent to 60,000 dpm) of tritiated cAMP and ATP were counted.
2. Membrane assay
Two days after plating into 10 cm dishes, approximately 1.5⋅109 cells were
scraped and suspended in PBS.After centrifugation (15 min; 500g) the cells
were homogenized in 10 ml solution containing 1mM NaHCO3, 1mM
dithiotreitol (DTT, Sigma, Steinheim, Germany), 0,2 mM magnesium
acetate (MgAc), 200 µg/ml DNaseI (Boehringer, Mannheim, Germany), and
protease inhibitors (Complete, EDTA-free, Boehringer, Mannheim,
Germany) at 4°C, using a Teflon on glass homogenizer. Homogenates were
centrifuged for 15 min at 1500g to remove intact cells and cell-debris.The
supernatant was centrifuged for 45 min at 40,000g and the final pellet was
resuspended in 1mM NaHCO3 + 1mM DTT. Total protein content was
determined using Bradford reagens with BSA as standard. Assay mixtures
contained 25 mM Tris acetate (pH 7.5), 5 mM MgAc, 0.5 mM ATP, 1 mM
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DTT, 0.1 mM IBMX, 0.1 g/l BSA, 10 µM GTP (Boehringer), 50 µM
cAMP, 1 µCi/ml [2,8-3H]-ATP (34.5 Ci/mmol, NEN, Boston, NA), 5 mM
phosphocreatine (Sigma, Steinheim, Germany) and 50 units/ml creatine
kinase (Sigma, Steinheim, Germany).The assay was started by adding 20 µg
of total membrane protein (contained in 60 µl) to 40 µl of assay mixtures
and compounds at the appropriate concentrations. Incubations were
performed at 30°C for 30 min. After incubation, samples were treated
identical as described above for the intact cell assay, except that 0.9 ml of stop
solution was added.Typically, from one sample a total amount of 2.3 pmoles
(equivalent to 180,000 dpm) of tritiated cAMP and ATP were counted.
Receptor expression
Bmax of the cell lines was determined in saturation experiments with [125I]-
NDP-MSH as tracer. NDP-MSH was iodinated using bovine lacto-
peroxidase (Calbiochem, La Jolla, CA) and 125I-Na (ICN, Aurora, OH)
according to Oosterom et al. [35] and subsequently high pressure liquid
chromatography-purified on a C18 column (µBondapak 3.9 X 300 mm,
Waters, Milford, MA). Cells were washed with tris buffered saline (TBS)
supplemented with 2.5 mM calcium chloride and incubated for 30 min at
room temperature with tracer diluted in Ham’s F10 medium (Gibco, Paisley,
Scotland) supplemented with 2.5 mM calcium chloride, 0.25% BSA and 200
KIU/ml aprotinin (Sigma, Steinheim, Germany).After two washes with ice-
cold TBS (+ 2.5 mM calcium chloride) the cells were lysed in 1M sodium
hydroxide and samples were counted in a γ-counter.
Data analysis
The Spearman correlation coefficient was determined to assess correlation
between receptor expression level and AC activity response to forskolin or
α-MSH. Differences in basal AC activity between the hMC4R expressing
cell lines were evaluated using the Student-Newman-Keuls test. Student’s t-
test was used to analyze the effect of AgRP(83-132) treatment on basal and
forskolin-induced AC activity. EC50 values were calculated with curve fitting
(non-linear, variable slope) using Prism software (GraphPad, San Diego,CA).
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Results
Constitutive activity of the hMC4R 
No specific [125I]-NDP-MSH binding was detected at wild type B16/G4F cells
(data not shown).Also, incubation of this celline with up to 1 µM α-MSH did
not induce adenylyl cyclase (AC) activity (Table 1), indicating that there is no
expression of endogenous MC receptors in this cell line.
Four clones of B16/G4F cells were generated, each with a different expression
level of functional hMC4R as measured by [125I]-NDP-MSH binding and
response to α-MSH (Fig. 1).The cell lines were tested for basal (unstimulated)
and forskolin-induced AC activity.The response to forskolin was determined
because it has been shown to correlate with the amount of constitutive activity
of receptors expressed in cell lines [36]. Basal AC activity was not significantly
different (0.54, 0.51 and 0.41 %cAMP) in three clones expressing 1.6⋅104,
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AC activities of wild type B16/G4F cells and B16/G4F cells expressing the  human MC3R or mouse
MC5R. Replicated two times.
Table I.
Figure 1. Spontaneous activity of the hMC4R.
Basal (♦) AC activity and the response to 1 mM
forskolin () and 1mM a-MSH () of four cell
lines expressing the hMC4R. AC activity
expressed as % of [3H]-ATP converted to [3H]-
cAMP is plotted against the receptor expression
level of the cell lines. Data are given as mean ±
s.e.m. (n = 3). Replicated four times.
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Figure 3. Dose-dependent suppression of hMC4R activity by AgRP(83-132). Effect of AgRP(83-
132) on basal (A) and forskolin (1 µM)-induced (B) AC activity in cells expressing the hMC4R
(23.104 receptors/cell). Data are shown as mean ± s.e.m. (n = 3). Replicated three times.
5.0⋅104 and 5.6⋅104 receptors/cell (clones MC4-1, MC4-2 and MC4-3,
respectively). However, significantly higher (1.26 % cAMP, p<0.05) AC activity
was detected in clone MC4-4, which expresses 23⋅104 receptors/cell (Figure 1).
The forskolin-induced AC activity correlated with the expression level of the
clones (Figure 1, r=0.97 and r=0.93 respectively, p<0.001).
Figure 2. Suppression of adenylyl cyclase activity by AgRP(83-132) in cells expressing the hMC4R.
Effect of 100 nM AgRP(83-132) on basal (A) and forskolin (1 µM)-induced (B) AC activity of wild
type (wt) B16/G4F cells and B16/G4F cells with different expression levels of the hMC4R. AC
activities of untreated (black bars) cells were set at 100% for each cell line. Relative AC activities of
cells treated with AgRP(83-132) are given in grey bars. Data are shown as mean ± s.e.m. (n = 3 or
4). * Statistically significant different (p<0.01). Replicated four times.
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Suppression of constitutive activity of the hMC4R by AgRP(83-132)
The effect of 100 nM human AgRP(83-132) on basal and forskolin-induced
AC activity of hMC4R expressing cells was determined (Figure 2).
AgRP(83-132) suppressed basal AC activity up to 60% in cells expressing the
hMC4R. This effect however, was not seen in clone MC4-1, which
displayed the lowest level of hMC4R expression. Similarly, AgRP(83-132)
suppressed forskolin-induced AC activity only in the three cell lines with the
highest expression of the hMC4R. Suppression of both basal and forskolin-
induced AC activity was most profound in cells with high expression levels
of the hMC4R.AgRP(83-132) did not alter basal and forskolin-induced AC
activity in wild type B16/G4F cells (Fig. 2).
AgRP(83-132) suppressed basal and forskolin-induced AC activity in a dose-
dependent manner (Fig. 3).The EC50 values were 21 and 37 nM, respectively.
1 µM SHU9119, identified as antagonist for the hMC4R [37], blocked the
effect of α-MSH on AC activity in a celline expressing the hMC4R at
3.6⋅104 receptors/cell (Fig. 4A). In this celline, SHU9119 also blocked the
effect of AgRP(83-132) on both basal and forskolin-induced AC activity
when co-administered (Fig. 4B and C). SHU9119 by itself did not influence
AC activity in these cells. Also in clone MC4-4, which expresses 23⋅104
receptors/cell and shows a larger response to AgRP(83-132), SHU9119 was
able to block the effect of AgRP(83-132) on basal AC activity (Fig. 4D).
However, in this clone SHU9119 displayed weak partial agonism, with an
efficacy of 4% of that of α-MSH (27% increase in AC activity for SHU9119
versus 730% increase for α-MSH, see Fig. 4D and 1, respectively).
To investigate the influence of receptor internalization, AgRP(83-132) was
also tested in a cell-free AC activity assay using membrane preparations
instead of intact cells. Incubation of membranes prepared from clone MC4-
4 with AgRP(83-132) reduced basal and forskolin-induced AC activity, but
did not affect AC activity in membranes from B16/G4F cells (Fig. 5).
The effect of AgRP(83-132) on the hMC3R and the mMC5R
Cells expressing the hMC3R (190⋅104 receptors/cell) and the mouse
(mMC5R, 54⋅104 receptors/cell) showed increased basal and forskolin-
induced AC activity compared to wild type cells (Table 1). Both cellines
99
Inverse Agonism of AgRP(83-132)
proefschrift wouter  04-02-2003  16:24  Pagina 99
Chapter 4
100
Figure 4. SHU9119 blocks the effect of AgRP(83-132) and α-MSH on the hMC4R. (A) Effect of 1
µM SHU9119 on α-MSH (1 µM )-induced AC activity in cells expressing the hMC4R at 3.9⋅104
receptors/cell. (B) Effect of 1 µM SHU9119 on inhibition of AC activity by 200 nM AgRP(83-132) in
the same celline as in (A). (C) Effect of 1 µM SHU9119 on the inhibition of forskolin-induced AC
activity by 200 nM AgRP(83-132) in the cells mentioned in (A). (D) Effect of 1 µM SHU9119 on the
inhibition of AC activity by AgRP(83-132) in clone MC4-4. Basal (A, B and D) and forskolin treated
(C) samples were set at 100%. Where multiple compounds were used in one sample, compounds
were added simultaneously. Abbreviations: MSH = α-MSH, S = SHU9119, F = forskolin and A =
AgRP(83-132). Data are expressed as mean ± s.e.m. (n = 3 for A,C and D, n = 4 for B). * Statistically
significant different from basal (A, B and D) or forskolin treated (C) (p<0.05). Replicated two (A, C
and D) and three (B) times.
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responded to α-MSH (Table 1). The hMC3R expressing cells and
membrane preparations from these cells showed 20-35% reduction in basal
and forskolin-induced AC activity upon incubation with 200 nM AgRP(83-
132) (Fig. 6). There was no effect of 200 nM AgRP(83-132) on basal and
forskolin-induced AC activity in cells expressing the mMC5R (data not
shown)
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Figure 5. AgRP(83-132) on hMC4R-
containing membranes. Effect of 200 nM
AgRP(83-132) on basal (A) and forskolin
(1 µM)-induced (B) AC activity in
membranes from clone MC4-4 and
B16/G4F cells. * Statistically significant
different (p<0.05). Replicated three times
Figure 6. Effect of AgRP(83-132)
on the hMC3R. Effect of 200 nM
AgRP(83-132) treatment (gray bars)
on basal (A), and forskolin (1 µM)-
induced  (B) AC activity of cells
expressing the hMC3R and
membranes of these cells. Bars
indicate mean ± s.e.m. (n =  4). *
Statistically significant different
(p<0.01) Replicated two
(membranes) and three (cells) times.
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Discussion
In this study, we show that the hMC4R displays constitutive activity in vitro
and that AgRP(83-132) acts as an inverse agonist for this receptor. These
findings represent a new mechanism by which melanocortin receptor
activity may be regulated in vivo.
AgRP(83-132) lowered dose-dependently both basal and forskolin-induced
AC activity in cells expressing the hMC4R.The data suggest that this effect
of AgRP(83-132) occurs via direct interaction with the hMC4R since this
effect was not seen in wild type B16/G4F cells and was blocked by 1 µM of
the MC4 antagonist SHU9119. Although at this high dose SHU9119
showed a partial agonistic effect on cells expressing the highest number of
hMC4R (clone MC4-4), this was only a small effect compared to the effect
of AgRP(83-132). Still, SHU9119 was able to fully block the effect of
AgRP(83-132). This is most likely via blockade of the hMC4R since
SHU9119 has nanomolar affinity for the hMC4R [37] and at 1 µM virtually
all receptors are occupied. It is not uncommon for antagonists to display
some intrinsic activity at high doses and high receptor expression levels.
The effect of AgRP(83-132) on AC activity was most profound in the cell
line with the highest hMC4R expression level. The effect was less in cells
expressing an intermediate level of the hMC4R and not detectable in cells
expressing very low amount of hMC4R.Thus, the efficacy of AgRP(83-132)
to suppress basal and forskolin-induced AC activity correlates with the
expression level of the receptor.
Inverse agonism is defined as the ability of a ligand to stabilize the inactive
conformation of a receptor [38]. The results discussed above suggest that
AgRP(83-132) is an inverse agonist for the hMC4R. However, the decreases
in AC activity observed here could also be due to hMC4R internalization
induced by AgRP(83-132), since AC activity correlates with receptor density
of a constitutively active receptor [39].To investigate the role of endocytosis
in the suppression of AC activity by AgRP(83-132), AC activity was
measured in cell membranes. During homogenization, the actin
cytoskeleton, which is necessary for endocytosis [40], is disrupted
mechanically. Additionally, endocytosis needs cytosolic components, which
are washed away during membrane preparation.Therefore it is expected that
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102
proefschrift wouter  04-02-2003  16:25  Pagina 102
endocytosis is severely impaired or absent in isolated membranes. Because
AgRP(83-132) suppressed constitutive activity of the hMC4R in membrane
preparations to the same extent as in intact cells, it is reasonable to conclude
that internalization is not the underlying mechanism for the effects of
AgRP(83-132) on the hMC4R. Therefore, based on the results that 1)
AgRP(83-132) suppressed AC activity via direct interaction with the
hMC4R, 2) this suppression depended on the expression level of the
hMC4R and 3) this suppression occurred in intact cells as well as in
membrane preparations, we conclude that AgRP(83-132) is an inverse
agonist for the hMC4R.
Because inverse agonism can only be measured in the presence of
constitutive activity, it is to be expected that in our test system the hMC4R
displays constitutive activity. Indeed, the response to 1 µM forskolin
correlated with the expression levels of the hMC4R.This was shown before
to be characteristic for constitutively active receptors [36].Also, compared to
the other hMC4R-expressing clones, the clone with the highest hMC4R
expression level showed elevated basal AC activity. These data strongly
support the notion that the hMC4R is constitutively active. However, basal
AC activity in the clones with lower hMC4R expression did not correlate
with the expression level of the receptor.This is not due to limited sensitivity
of the assay, because upon incubation with AgRP(83-132) lower AC activity
could be measured in these clones. One obvious explanation is that
intracellular compensatory mechanisms exist which are able to counteract
basal constitutive activity only at low expression levels of the receptor. At
higher expression levels of the receptor (as in clone MC4-4) or in the
presence of forskolin these mechanisms may not be able to compensate for
constitutive activity.Thus, in these experiments the use of forskolin allows a
more sensitive detection of constitutive activity, as had been described before
[36].
Both expressing the hMC3R or the mMC5R in B16/G4F cells increased
basal and forskolin-induced AC activity.This indicates that both receptors are
constitutively active. As is shown in figure 6, AgRP(83-132) is an inverse
agonist also for the hMC3R. In contrast, although the mMC5R has
constitutive activity, AgRP(83-132) did not affect AC activity in cells with
this receptor. This is in agreement with the low affinity of AgRP for the
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MC5R [12,21,22].
Several lines of evidence suggest that activation of central MCR inhibits
food intake [1,3]. If the hMC4R exhibits constitutive activity in vivo this
would contribute to the tonic inhibition of the melanocortin system on
feeding. The observed haploinsufficiency of obese human subjects with
hMC4R-gene variants reported in several studies [5,6,41] and the
intermediate obese phenotype of mice heterozygous for MC4R deletion [1]
may therefore be the result of a gene dosage effect resulting in decreased
constitutive activity. However, it can not be excluded that an impaired
response to α-MSH in the heterozygous mutants causes the
haploinsufficiency.
Most likely, full-length AgRP also acts as an inverse agonist because the C-
terminus of AgRP has been shown to possess the same pharmacological
properties in vitro and in vivo as full length AgRP [22,24,27]. Furthermore,
other studies already showed effects of nearly full-length AgRP that do not
fit with neutral antagonism [12,27].
This indicates that AgRP may reduce the activity of the melanocortin
system independently of α-MSH in the brain. Proopiomelanocortin
(POMC) and AgRP are expressed in different neurons [42,43]. If AgRP(83-
132) only blocks α-MSH-induced activation, the presence of α-MSH (i.e.
activation of POMC neurons) is necessary for AgRP to function. However,
if AgRP acts independent of α-MSH, AgRP containing neurons can act
independently of POMC containing neurons, thereby adding a new level of
regulation to the melanocortin system. Indeed, in rat brain AgRP- and α-MSH
production seem to be counterregulated since there is increased AgRP mRNA
and decreased POMC mRNA expression in response to fasting [44,45]. The
opposite effect is seen in response to leptin [26,42,44-46].Interestingly,the changes
in AgRP mRNA levels are larger than those measured for POMC [25].Thus, for
the regulation of body weight the melanocortin system may be controlled more
by AgRP than α-MSH.Similarly, for the MC1R it is the expression level of agouti
rather than that of α-MSH which determines the coat color [13].
The data presented here form a basis to further investigate the relevance of
constitutive activity of the MC4R and of inverse agonism of AgRP for the
regulation of body weight.
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Abstract
The melanocortin-4 receptor (MC4R) plays an important role in the regulation of body
weight in rodents. Mutations in the coding region of the MC4R are found more frequent
in obese individuals as compared to non-obese individuals, supporting the hypothesis that
also in humans deficient melanocortin signaling may lead to obesity. Family studies that have
been carried out to demonstrate relevance of single mutations for obesity were mostly
inconclusive, most likely due to small sample size and complexity of the trait. In addition,
the existing pharmacological data of the mutant receptors is limited in that for most
mutations the effect on receptor expression level and AgRP pharmacology have not been
studied. The aim of the present study was to gain further insight into the impact of the
MC4R mutations on receptor function. Eleven missense mutations were tested for cell
surface expression, affinity for α-MSH and AgRP(83-132) and the biological response to α-
MSH. All mutants were poorly expressed at the cell surface, as measured by 125I-[Nle4, D-
Phe7]-α-MSH binding, and only a few mutants showed altered pharmacology for α-MSH
and AgRP. HA-tagged mutant receptors were retained in the intracellular environment.
These pharmacological data provide a basis to estimate the quantitative effect of MC4R
mutations for the development of obesity.
Chapter 5
110
proefschrift wouter  04-02-2003  16:25  Pagina 110
Introduction
The melanocortin-4 receptor (MC4R) is expressed in the brain, including
hypothalamic areas that influence food intake and energy expenditure [1].
Several lines of evidence have indicated involvement of the MC4R in the
regulation of body weight in rodents. Ectopic over-expression of the
MC1R/MC4R antagonist agouti protein in the brain results in obesity in
mice [2-4]. Agouti-related protein (AgRP), which shares homology with
agouti, blocks MC3R and MC4R signaling by acting as an inverse agonist
[5]. Similar to agouti protein, over-expression of AgRP results in an obese
phenotype in mice [6]. Finally, null-mutant mice lacking the MC4R gene
develop late-onset obesity with hyperglycemia and hyperinsulinemia [7].An
intermediate obese phenotype was found for heterozygous null-mutants,
suggesting a gene-dosage effect. Whereas in normal mice application of
melanocortin agonists decreased, and (MC4R-selective) melanocortin
antagonists increased food-intake and body weight [8,9], these effects were
not seen in the MC4R -/- mouse [10].Together, these data show that under
normal conditions, MC4R activation serves to prevent development of
overweight, and that disruption of this signal leads to obesity.
Genetic studies have implicated a role for the melanocortin system in body
weight regulation of humans. Mutations causing defects in synthesis or
processing of pro-opiomelanocortin (POMC), which encodes the
melanocortin agonist α-MSH, lead to obesity [11]. In the MC4R, four
frameshift mutations, one nonsense mutation and twenty-four missense
mutations have been found, most of which have only been found in obese
individuals [12-21]. This suggests that mutations in the MC4R predispose
for development of obesity. The incidence among obese individuals was
estimated to be as high as 4%, which would make it the most common
monogenic form of obesity [17].
Family studies have been carried out for several of the mutations to
investigate the role of these mutations in obesity. For one frameshift
mutation and one nonsense mutation, post hoc analysis yielded LOD scores
>3 [22].Yeo et al. [12] reported a LOD score of 1.5 for the same frameshift
mutation. However, for most mutations causality is still ambiguous, although
most family members that carried these mutations were also obese [15-17].
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In these studies, determination of penetrance was hindered by small
pedigrees and the complexity of body weight control. For instance, some
families may already be predisposed for obesity due to environmental and/or
other genetic factors [22]. This could explain that phenotypes of carriers
varied from no obesity to extreme obesity [16-18], as is exemplified by the
lack of cosegregation of a frameshift mutation that may be considered a loss
of function mutation, with obesity [17]. Also, in one study, deletions in the
chromosomal region that contains the MC4R were not associated with
obesity [23]. Thus, although mutations in the MC4R predispose for
development of obesity, not for every individual mutation its role in the
pathogenesis of obesity is clear, and susceptibility to MC4R mutations may
vary between individuals.
Pharmacological evaluation of mutant receptors gives more insight into the
impact of the mutation on receptor function at the molecular level and may
be helpful to determine the quantitative effect of a mutation in mutation
carriers. Since most of the mutations in the MC4R result in non-
conservative amino acids changes, it seems likely that these mutations affect
receptor function rather than that they are in complete linkage
disequilibrium with disease mutations elsewhere in the gene. As outlined
above, loss of function is expected from MC4R mutations that cause obesity.
Indeed, several mutant MC4Rs were shown to have impaired or no
functionality in vitro [15-17], whereas mutations that have been found with
similar frequency in non-obese individuals did not affect receptor function
[17,24]. For most mutants that have been tested however, only agonist
binding and potency were determined and for only two mutant receptors
the cell surface expression level has been determined [15,24], whereas this is
often reduced as result of a mutation. Since AgRP is an endogenous ligand
for the MC4R, differences in its affinity can be expected to affect MC4R
activity as well. Therefore, we extended the existing functional studies by
assessing the effect on cell surface expression, affinity and activity of α-MSH
and affinity of AgRP for eleven of the MC4R mutations.
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Materials and methods
Peptides and chemicals
Forskolin was purchased from Sigma (Steinheim, Germany) and synthetic
human AgRP(83-132) was obtained from Phoenix Pharmaceuticals, Inc
(Mountain view, CA). α-MSH and [Nle4,D-Phe7]-α-MSH (NDP-MSH)
were purchased from Bachem (Bubendorf, Switzerland).
Construction of mutant receptors
The human-MC4R cDNA (Genbank L08603) was used as a template.The
receptor cDNA was cloned in pcDNA3 (Invitrogen, Carlsbad, CA) and
maintained in the E.coli DH5α strain.The mutations were introduced with
a polymerase-chain reaction (PCR) strategy using PFU polymerase
(Stratagene, La Jolla, CA) and PFU buffer (Stratagene, La Jolla, CA). Per
reaction, two complementary primers that contained the mutations were
used.The reactions yielded complete copies of both complementary strands
of the plasmid, which readily can be transformed into bacteria.The primers
used were (per mutation, only the primer homologous to the coding strand
is given from 5’ to 3’ end):
Ser30Phe: CTGCACAGCAACGCGTCTGAGTTCCTTGGAAAAGGC,
Pro78Leu: CTGCATTCACTCATGTACTTTTTCATATGCAGCTTGG,
Thr112Met: CTATTAAACAGTACTGATATGGATGCACAG ,
Arg165Trp: CCATAACATCATGACAGTTAAGTGGGTTGGGATC,
Arg165Gln: CCATAACATCATGACAGTTAAGCAGGTTGGGATC,
Ile170Val: GGTTGGGATCATCGTAAGTTGTATCTGGG ,
Gly252Ser:
GCGATTACGTTGACCATCCTGATTAGCGTCTTTGTTGTCTGCTG,
Ile317Thr:
CTGAGGAAAACCTTTAAAGAGATCACCTGTTGCTATCCCCTGGG,
Ile137Thr:
CCTTGCTTGCATCCACCTGCAGCCTGCTTTCAATTGC,
Leu250Gln: CCTTGACCATCCAGATCGGCGTCTTTGTTGTCTGC,
Ile301Thr:
CAATCATCGATCCTCTGACTTATGCATTACGGAGTCAAG,
Val253Ile: GACCATCCTGATCGGCATCTTTGTTGTCTGC.
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Reaction mixtures (40 µl end volume) consisted of 20 ng template DNA,
35 ng DNA of each primer, 500 µM dNTP’s (Amersham Pharmacia,
Piscataway, NJ) and 3 units of PFU polymerase (Stratagene, La Jolla, CA) in
the appropriate buffer concentration.The cycling parameters were: 95°C for
30 sec, followed by sixteen cycles of denaturation at 95°C for 30 sec,
annealing at 50°C for 1 min and extension at 60°C for 13 min, and at the
end of the reaction an extension step at 68°C for 20 min. Reaction samples
were then cut with DpnI to fragmentate methylated template DNA and
subsequently transformed into E.coli DH5α.The entire coding region of the
receptor and upstream sequences of each construct were verified by
sequence analysis.
Construction of HA-tagged receptors
The WT and three of the mutant receptors were N-terminally tagged with
an HA-tag using a PCR strategy. Sequences of the primers that were used
are as follows (5’ to 3’):
(1) CCATATGATGTTCCAGATTATGCTATGGTGAACTCCACCCACCG,
(2) AGTCTCGAGACCTGCGTTAATATCTGCTAGACAAG,
(3) ATCAGAATTCGGCCACCATGTATCCATATGATGTTCCAGATTATGC.
Two consecutive PCR reactions were performed, the first using WT or
mutant receptor DNA as template and primers (1) and (2).The second PCR
used the product of the first PCR as template and primers (2) and (3).The
reaction mixtures (20 µl) contained 10 ng template DNA, 30 ng per primer,
200 µM dNTP’s (Amersham Pharmacia, Piscataway, NJ) and 2 units of PFU
polymerase (Stratagene, La Jolla, CA).The cycling parameters were: 95°C for
5 min, thirty cycles of 95°C for 30 sec, 50°C for 30 sec and 72°C for 2 min,
followed by 72°C for 10 min.These reactions insert an HA tag immediately
upstream of the start codon of the MC4R gene, preceded by a consensus
Kozac sequence and an EcoRI site. N-terminally, a BspMI and XhoI site are
inserted after the stop codon of the MC4R gene.The PCR products were
cloned in pcDNA3 (Invitrogen, Carlsbad, CA) using the EcoRI and XhoI
sites and subsequently verified by sequence analysis.
Cell culture and transfection
HEK293 and BHK cells were grown in Dulbecco’s modified Eagles’
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medium, supplemented with 10% fetal calf serum (Integro, Zaandam, the
Netherlands), 2 mM glutamine (Gibco, Paisley, Scotland) and non-essential
aminoacids (NEAA, Gibco, Paisley, Scotland). All transfections were done
using standard calcium phosphate precipitation. For binding experiments
and the adenylate cyclase assay, receptors were transiently expressed in
HEK293 cells by transfecting cells growing in 10-cm dishes with 7 µg
DNA. For the reporter gene assay, cells growing in 10-cm dishes were co-
transfected with 200 ng receptor DNA and 7 µg of CRE-LacZ construct
[25]. The immunocyotochemical studies used BHK cells that were
transfected with 1.4 µg DNA per well of a six-well plate.
To allow determination of transfection efficiency, cells were cotransfected
with a LacZ construct. Two days later, the cells were fixed in 2%
paraformaldehyde/0.2% glutaraldehyde for 15 minutes, and washed with
phosphate-buffered saline (PBS). By adding freshly prepared substrate
solution (1 mg/ml X-gal, 5 mM potassium ferricyanide, 5 mM potassium
ferrocyanide , 2 mM MgCl2 in PBS), β-galactosidase positive cells were
stained.
Binding assay
IC50 values were determined with 125I-[Nle4, D-Phe7]-α-MSH as tracer.
[Nle4, D-Phe7]-α-MSH was iodinated using bovine lacto-peroxidase
(Calbiochem, La Jolla, CA) and 125I-Na (ICN, Aurora, OH) according to
Oosterom et al. [26] and subsequently high pressure liquid chromatography-
purified on a C18 column (µBondapak 3.9 X 300 mm, Waters, Milford,
MA).
48 hours after transfection, cells growing in 24-wells plates were washed
with tris-buffered saline (TBS) supplemented with 2.5 mM calcium chloride
and incubated for 30 min at room temperature with peptides and tracer
diluted in Ham’s F10 medium (Gibco, Paisley, Scotland) supplemented with
2.5 mM calcium chloride, 0.25% bovine serum albumine (BSA) (ICN,
Aurora, USA) and 200 KIU/ml aprotinin (Sigma, Steinheim, Germany).
After two washes with ice-cold TBS (+ 2.5 mM calcium chloride) to
remove non-bound tracer. The cells were then lysed in 1M sodium
hydroxide and samples were counted in a γ-counter.
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Adenylyl cyclase assay
Adenylyl cyclase activity was determined using a modified method of
Salomon [27]. Cells were grown in 24-well plates and incubated for two
hours with 2µCi/ml [3,8-3H]-adenine (21.7 Ci/mmol, NEN, Boston, NA)
in assay medium (Dulbecco’s modified Eagle’s medium (Gibco, Paisley,
Scotland) containing 0.2% bovine serum albumine (BSA, CN,Aurora, OH),
2 mM L-glutamine (Gibco, Paisley, Scotland) and non-essential amino acids.)
Subsequently, the cells were washed with assay medium containing 0.25 mM
isobutylmethylxanthine (IBMX, Sigma, Steinheim, Germany) and incubated
for 20 min with compounds diluted in assay medium with 0.25 mM IBMX.
Then 1 ml of cold stop solution (5% trichloric acid (Merck), 1 mM cyclic
adenosine monophosphate (cAMP, Boehringer, Mannheim, Germany), 1
mM adenosine triphosphate (ATP, Boehringer, Mannheim, Germany)) per
well was added and the plates were centrifuged at 250g. Finally, ATP and
cAMP fractions were separated on dowex (AG-50W-X4, Bio-Rad, Hercules,
CA), respectively alumina (WN-3, Sigma, Steinheim, Germany) columns.
ATP and cAMP fractions were dissolved in scintillation cocktail (Ultima
Gold, Packard, Meriden, CT) and counted in a β-counter.
The equation [3H]-cAMP/([3H]-cAMP + [3H]-ATP) was used to calculate
AC activity as the percentage of [3H]-ATP that is converted to [3H]-cAMP.
Reporter gene assay 
In this assay, LacZ is used as a reporter gene [25].The cells were dispensed
into 96-wells plates (BectonDickinson) and two days later incubated with
peptides at the appropriate concentrations in serum-free medium (DMEM
containing 0.2% BSA (ICN, Aurora, USA) glutamine (Gibco, Paisley,
Scotland) and non-essential aminoacids (Gibco, Paisley, Scotland)).After 5-6
hours of incubation, the assay medium was aspirated and 40 µl of lysis buffer
(PBS containing 0.1% triton-X-100 (Boehringer, Mannheim, Germany))
was added. The plates were stored at -20°C and after thawing 80 µl of
substrate mix (0,1 M phosphate buffer, pH7.4 containing 1.6 g/l o-
Nitrophenyl β-D-galactopyranoside (ONPG, Molecular probes, Leiden, the
Netherlands), 67.5 mM β-mercaptoethanol (Merck, Darmstadt, Germany)
and 1.5 mM magnesium chloride) was added. Absorbance at 405 nm was
determined in a Victor2 microplate reader (PerkinElmer, Brussels, Belgium).
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Immunocytochemistry 
For immunocytochemical experiments with HA-tagged receptors, BHK
cells were used, since they attached better to glass coverslips as compared to
HEK293 cells, which were washed away during the procedures. Cells
growing on glass coverslips were transfected overnight with receptor DNA
and after 48 hours fixed in 4% paraformaldehyde and washed quickly two
times in phosphate buffered saline (PBS). After incubation (30’ at room-
temperature) in TNB blocking buffer (provided with Tyramide Signal
Amplification kit, Perkin Elmer, Boston, MA), cells were incubated
overnight at 4°C with horseradish peroxidase-conjugated rabbit anti-HA
antibodies (Roche, Basel, Switzerland) diluted in TNB buffer supplemented
with 0.05 % triton TX-100.The samples were washed three times for 5’ with
PBS containing 0.05 % Tween 20. The Tyramide Signal Amplification kit
with FITC labeled streptavidin was used according to manufacturers’
instructions to stain positive cells. The coverslips containing the cells were
mounted onto glass slides with 1,4-Diazabicyclo (2,2,2)-octane (DABCO)
/mowiol and viewed with a TCS NT confocal laser-scanning microscope
(Leica, Heidelberg, Germany).
Results
MC4R mutations were taken from four genetic studies that had identified
these mutations in obese individuals [14,15,16,17]. In these studies together,
the MC4R of 898 obese patients and 368 non-obese controls (including
anorexia nervosa patients, bulimia nervosa patients and underweight
individuals) was analyzed by single-strand conformational polymorphism
(SSCP) analysis or sequencing.Two silent mutations, one nonsense mutation,
three frameshift mutations and twenty different missense mutations were
found in the coding region of the MC4R (Table I). Of the missense
mutations that have only been found in obese individuals, five mutations that
had not been pharmacologically tested before, and six additional mutations
were analyzed further in the present study. Mutations in the N-terminus
were not included since it was shown before that the N-terminal part of the
MC4R is not important for ligand binding [28].The silent mutations were
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not included because it is very unlikely that these mutations result in any
alteration in receptor function.The frameshift and nonsense mutations were
also not included since they most likely lead to nonfunctional receptors,
which was already shown for one frameshift mutation [24].
No differences in transfection efficiency or cell survival/growth were
observed between cells transfected with either WT or mutant receptor DNA
(data not shown), excluding that differences in the number of cells would
account for effects measured in the binding and activation assays.
1. Binding studies 
To compare the cell surface expression of the mutants with that of the wild
type (WT) receptor, specific binding of 125I-[Nle4, D-Phe7]-α-MSH tracer to
HEK293 cells that were transfected either with WT or mutant receptor
DNA was assessed, as well as the IC50 value of [Nle4, D-Phe7]-α-MSH
(NDP-MSH) for these receptors. As can be seen in Fig.1, only the T112M
mutant showed specific binding that resembled that of the WT receptor, but
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« Table I. Summary of pharmacological data and family studies of the mutations that were found in
four studies of which the mutants were taken [14,15,16,17]. For the silent mutations, the number
refers to the base sequence, for the other mutations the number indicates the codon at which the
mutation occurs.When available, the effect on EC50 and Kd values and the maximal effect  (Emax) of
α-MSH (MSH) or [Nle4, D-Phe7]-α-MSH (NDP) as compared to the wild type receptor is given,
followed by the factor by which these values differ from those of the wild type receptor. Equal EC50
and Kd values are denoted by “=”, and increases or decreases by “↑” and “↓”, respectively. Non-obese
indicates that anorexia nervosa or bolumia nervosa patients belong to the group [14].The mutants
that were tested in this study are given in bold.
Figure 1. Specific binding of
125I-[Nle4, D-Phe7]-α-MSH
(NDP-MSH) to cells
expressing either the wild
type (WT) hMC4R, or the
mutant receptors. Average
binding (± s.e.m) as
compared to that of the WT
receptor from three
independent experiments is
given.
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for the other mutants binding was decreased.This was most pronounced for
the P78L mutant, which showed virtually no specific binding of tracer.The
IC50 values of NDP-MSH for the mutants indicate that the lower specific
binding was not due to decreased affinity for the tracer (Table II), but rather
that cell surface expression of the mutant receptors was decreased. In fact,
the reduced IC50 values of NDP-MSH for the T112M, I301T and L250Q
mutants suggest that these mutants have increased tracer affinity and thus
relative cell surface expression would be over-estimated when using specific
tracer binding at a single concentration. To test this, the cell surface
expression levels of the L250Q and T112M mutants were determined more
directly with saturation experiments (Fig. 2). Both these mutants showed a
decreased Bmax (16% and 41% of the WT receptor, respectively), and the Kd
values are in agreement with the IC50 values obtained from the displacement
studies (Table II).
Gu et al. [15] reported decreased affinity of the I137T mutant for 125I-[Nle4,
D-Phe7]-α-MSH, and no changes in cell surface expression, whereas our
results indicate that affinity is not changed but rather cell surface expression
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Figure 2. Saturation curves of 125I-[Nle4, D-
Phe7]-α-MSH (NDP-MSH) for the WT MC4R
and the T112M and L250Q mutants.The Kd (±
s.e.m) values were determined using
Scatchard analysis of  the data. Data shown is
from a single experiment.
Figure 3. Saturation curves of 125I-[Nle4, D-
Phe7]-α-MSH for the WT MC4R and the
I137T mutant. Kd values ± s.e.m. are given in
parenthesises and were calculated with
Scatchard analysis. Data shown is from a single
experiment.
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is impaired for this mutant.To confirm our data, saturation experiments were
also performed with this mutant. We found no differences in affinity as
compared to the WT receptor, but the Bmax was reduced for the I137T
mutant (Fig. 3).
Next, the affinities of α-MSH and AgRP(83-132) for the mutants were
determined (Table II). It has been shown before that the AgRP(83-132)
fragment contains the pharmacologically active sequence of AgRP for
melanocortin receptors [29-31]. Most mutants showed similar α-MSH
affinity as the WT receptor, but it was increased two-fold for the T112M and
I301T mutants and ten fold for the L250Q mutant. No decreases in
AgRP(83-132) affinity were found, but similar to α-MSH, AgRP(83-132)
affinity was increased for some mutants, which was most pronounced 
on the T112M, I301T and the L250Q mutants.The ratio IC50(MSH)/IC50(AgRP)
remained constant for most mutants, except for the L250Q and
S30F/G252S mutants, which showed a decreased and increased ratio,
respectively.
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Table II.
IC50 values (nM) ± s.e.m. of [Nle4, D-Phe7]-α-MSH, α-MSH and AgRP(83-132) for the wild type (WT)
MC4R and the mutants, using 125I-[Nle4, D-Phe7]-α-MSH as tracer. Data represent average of four
independent experiments. “-“ indicates that no IC50 value could be obtained.
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2.Activation studies 
It is well known that depending on the activation assay that is used (e.g.
measuring genomic response or a more direct G-protein/effector response),
different EC50 values of a ligand for the same receptor can be measured.Also,
a receptor reserve may exist in a sensitive assay, masking differences in the
number of maximally activated receptors. Therefore, in this study we used
both a more direct adenylate cyclase (AC) assay and a sensitive LacZ reporter
gene assay [25] to measure receptor activation. In the AC assay, dose-response
curves were obtained for all mutants, except for the P78L mutant, which did
not show any activation by α-MSH at concentrations up to 1 µM. The
maximal effect elicited by α-MSH (Emax) was decreased for all mutants as
compared to the WT receptor (Table III), and correlated with the cell
surface expression level of the mutants (Fig. 4). Only for the I137T and
S30F/G252S mutants, a decrease in potency of α-MSH as compared to the
WT receptor was found (ten fold increase in EC50 value).
In the LacZ assay, α-MSH responses were already measured at lower receptor
expression levels as compared to the AC assay (data not shown). Most
mutants showed an EC50 value that was comparable to that of the WT
receptor, with again the I137T and S30F/G252S mutants showing an
increased EC50 value (four and three fold, respectively) (Table III). The
L250Q mutant displayed basal activity that was almost as high as the maximal
α-MSH response of the WT receptor (Fig. 5) and further increase of activity
by α-MSH was too small to obtain accurate EC50 values. In contrast to the
AC assay, the maximal α-MSH responses of the mutants did not differ from
that of the WT receptor. However, expression of different amounts of WT
receptor also had no effect on maximal α-MSH response (Fig. 6).
3. Immunocytochemistry 
We further explored the cellular distribution of HA-tagged forms of the WT
receptor and the P78L, R165W and R165Q mutants, which showed the
largest decrease in tracer binding, using an anti-HA antibody (Fig.7).The WT
receptor showed a diffuse staining, which was also present at the cell surface.
In contrast, the three mutants showed a staining that was much more
concentrated around the nucleus, and the staining at the cell surface was
absent.
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Figure 5. Dose-response curves
of the WT MC4R and the L250Q
mutant as determined in the LacZ
assay.
Figure 6. Dose-response curves
of α-MSH obtained in the LacZ
assay, for cells that were transfected
with different amounts of WT
receptor DNA. The expression
levels of the different transfections,
as confirmed by binding of 125I-[Nle4,
D-Phe7]-α-MSH, were in the range
of those of the mutant receptors.
Experiment was repeated three
times with similar results.
Figure 4. Maximal α-MSH
response as measured in the AC
assay versus cell surface expression
of the WT and mutant MC4Rs. For
the T112M and L250Q mutants, the
expression levels obtained from the
saturation curves are used.The data
of the I301T mutant are not
included, since this mutant has
increased affinity for [Nle4, D-Phe7]-
α-MSH and the binding data as
presented in Fig. 1 is not
representative for its expression
level relative to that of the WT
receptor. Pearsons correlation
coefficient = 0.88; p<0.001.
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Discussion
All of the MC4R mutations that were tested here resulted in poor cell
surface expression and for only two mutants decreased efficacy (increase in
EC50 value) of α-MSH was found. Some mutants even displayed increased
affinity for α-MSH and AgRP(83-132). Table IV summarizes the
pharmacological characteristics of the mutant receptors. These data agree
with significance of the mutations for receptor function, and add support to
the hypothesis that these mutations are pathogenic factors that contribute to
obesity.This also underscores the importance of the MC4R for body weight
regulation in humans, homologous to its role in rodents.
The decreases in maximal α-MSH response as observed in the AC assay
correlated well with  decreases in cell surface expression levels, supporting
the conclusion that these altered α-MSH responses are due to the lower
Chapter 5
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EC50 ± s.e.m. and Emax values of α-MSH for the mutant and WT receptors in the AC assay and the
LacZ assay.The data of the AC assay represent the average of three, and for the LacZ assay of four
independent experiments.
Table III.
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expression levels. In contrast, differences in maximal α-MSH response of the
mutants were not measured in the reporter gene assay. Apparently under
these assay conditions the maximal response is not influenced by cell surface
expression level, as was demonstrated by transfection of different amounts of
WT receptor DNA.The EC50 values in the reporter gene assay were lower
than those obtained in the AC assay, suggesting that at low receptor
occupancy, a maximal response was already reached. This indicates the
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Figure 7. Immunostainings of BHK cells transfected with HA-tagged forms of either the WT, P78L,
R165W or R165Q receptors. White arrows indicate staining at the cell surface. The full shape of
mutant-transfected cells cannot be seen because the staining is concentrated round the nucleus.
A colour version of this figure is printed on the back of this thesis.
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existence of a receptor reserve in the reporter gene assay, probably due to the
high sensitivity of this assay and high receptor expression, which explains
that differences in cell surface expression did not influence maximal receptor
activation. Thus, for the MC4R mutants that were tested, lower α-MSH
responses in the AC assay were most likely due to decreased cell surface
expression. This impaired function fits well with the obese phenotype of
mutation carriers, and decreased cell surface expression may therefore be the
mechanism underlying the increased risk for obesity of these individuals.The
observation that mice lacking one MC4R allele have intermediate body
weight as compared to wild type and homozygous knock-out animals also
Chapter 5
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Summary of the effect of the mutations on receptor function. For each mutant, the cell surface
expression as percentage of the WT receptor is given. CAM = constitutively active mutant.
a For the T112M and L250Q mutants, the expression level as determined in the saturation
experiments is given.
b For the I301T mutant, the relative specific binding of 125I-[Nle4, D-Phe7]-α-MSH as depicted in Fig.
1 is given. However, since this mutant has increased affinity for the tracer, it is probably expressed at
lower levels as indicated in Fig. 1.
Table IV.
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supports that MC4R expression is important for maintaining normal body
weight. Still, a dominant-negative mechanism can not be ruled out, although
Ho et al. [24] showed that two frameshift mutations are retained intracellular,
but do not affect wild type receptor function when expressed in the same cell.
The above demonstrates the importance of determining cell surface
expression level when analyzing the pharmacology of mutant receptors,
since it is a parameter that is often affected, and it can influence the outcome
of activation studies. Impaired cell surface expression resulting from
mutations that are linked with diseases are also seen in other receptor
systems, indicating that the total amount of cell surface receptors is indeed
important for normal function. For instance, the majority of mutant
vasopressin-2 receptors that are found in patients with nephrogenic diabetes
insipidus fail to reach the cell surface [32,33]. Based on our data, it can
therefore be hypothesized that mutations in the regulatory region of the
MC4R gene that affect receptor expression are also enriched in obese
populations. Consequently, future studies may identify such regulatory
mutations and the percentage of obese individuals that have defects in
MC4R signaling could be higher than has been estimated until now.
The pharmacology of α-MSH and AgRP(83-132) for the mutants was
generally similar to that of the WT receptor, but lower potency of α-MSH
was found for the I137T and S30F/G252S mutants. Since this was not due
to decreased affinity of α-MSH for these receptors (for the I137T mutant
α-MSH affinity was actually higher), G-protein coupling seems impaired for
these mutants. In addition, the S30F/G252S mutant showed increased
affinity for the inverse agonist AgRP(83-132). Thus, for these mutants,
changes in pharmacology for the endogenous ligands may be an additional
mechanism resulting in decreased melanocortin signaling in vivo, and thereby
contribute to an increased risk for development of obesity. Interestingly, the
ratio of the affinities for α-MSH and AgRP(83-132) remained constant for
most mutants, including the T112M and I301T mutants, whose affinities
differed two fold from those of the WT receptor.These data suggest that the
binding of α-MSH to the MC4R is affected similarly to that of AgRP(83-
132) by these mutations. Similar results were previously obtained for binding
of a selective agonist and the antagonist agouti protein to the MC4R [34].
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In contrast to Vaisse et al. [17], we found no increased EC50 values for the
R165W, I170V and I301T mutants. However, EC50 values increase with
lower receptor numbers in case there is a receptor threshold for measuring
activity. Since these authors reported lower specific binding for the mutant
receptors as compared to the WT receptor, a receptor threshold in their
study could explain the differences with our results. Gu et al. [15] found that
for the T112M mutant, the EC50 value of α-MSH was not affected, which
seemed in line with the occurrence of this mutant in a lean individual.
However, here this mutant was shown to be poorly expressed, and the fact
that it was found in a lean individual may thus be due to compensatory
factors of  this individual to MC4R impairment, like for the lean carriers of
a MC4R nonsense mutation [17]. In addition, Gu et al. [15] reported
decreased affinity of the I137T mutant for [Nle4, D-Phe7]-α-MSH, whereas
we found decreased expression rather than differences in [Nle4, D-Phe7]-α-
MSH affinity.There is no obvious explanation for these differences, but since
both studies found decreased potency of α-MSH for this mutant, it may be
concluded that it has an impaired α-MSH response.
Consistent with the data of Vaisse et al. [17], the L250Q mutant displayed
high constitutive activity in the reporter gene assay. The enhanced basal
activity of this receptor may be considered a gain of function, which would
not fit with an obese phenotype. However, as for many CAM receptors [35],
cell surface expression level of the L250Q mutant was decreased. Even more,
the constitutive activity may actually be low and physiologically
insignificant, because it was not measured in the less sensitive AC assay.
Therefore, the net result of this mutation in vivo can still be impairment of
melanocortin signaling.
Assessing the quantity of impairment in receptor function due to mutations
may help to determine the influence of these mutations on body weight. Of
the mutations tested here, clinical data only of carriers with the R165W,
I170V, L250Q and I301T mutants has presently been reported [17] and
family studies have been carried out for the I170V, I137T, R165W, I301T
mutants [15,17,18]. However, more phenotypical data of mutation carriers
are probably needed before correlations between these two parameters can
be made.
The immunocytochemical data suggest that the P78L, R165W and R165Q
Chapter 5
128
proefschrift wouter  04-02-2003  16:25  Pagina 128
mutants are expressed, but are retained intracellular.This may also be the case
for the other mutant MC4Rs that were tested here, since two frameshift
mutations were also shown to be expressed, but failed to reach the cell
surface [24].
Many mutant receptors that have poor cell surface expression, including
CAM receptors, can be rescued to the cell surface upon ligand binding [35-
37]. Pharmacological interventions aimed at treating the obesity of
individuals with MC4R mutations may thus be directed towards
stabilization of MC4R at the cell surface, preferably combined with receptor
activation. Also for the development of MC4R agonists to treat obesity in
general, screening for stabilization of the MC4R at the cell surface may be
important, since our data suggest that modest decreases in MC4R expression
are associated with increased body weight.
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The studies described in this thesis concern the pharmacological properties
and physiological roles of the MC4R. New, selective agonists were
developed, which were used to strengthen involvement of the MC4R in a
model of neuropathic pain, and to indicate that the MC4R is probably not
the receptor that mediates the stimulating effects of melanocortin ligands on
sensory recovery after peripheral nerve damage. It was also shown that the
MC4R is constitutively active and that the endogenous ligand AgRP is an
inverse agonist. Furthermore, MC4R mutations that occur more frequently
in obese individuals were found to be poorly expressed at the cell surface.
Identification and in vivo evaluation of selective
compounds
Of the five melanocortin receptors that have been cloned, the MC4R has
gained much interest because of its involvement in body weight regulation.
Since the MC3R and MC4R are the predominant MCRs in the brain, they
may mediate other reported central effects of melanocortins, like
inflammation and thermoregulation. However, the molecular basis for these
effects are currently not well understood. Ligands with selectivity for a
certain receptor subtype are very useful tools to determine the physiological
role of that receptor. Although antagonists with selectivity for the MC4R
have been available for some time, selective agonists for this receptor have
been lacking.The selective compounds JK1 and JK9, which are described in
chapter 2, are among the first MC4R selective agonists to be identified and
should prove to be useful tools in elucidating the role of the MC4R in
several physiological processes.Although mice lacking a MCR subtype have
already been very useful in doing so, this approach has some limitations. For
instance, with deletion of a receptor, acute effects of receptor activation or
blockade can not be studied, whereas these effects may differ from the long
term effects. Also, adaptations that compensate for the absence of a protein
may occur. This is probably the case in NPY and AgRP knockout mice,
which have normal body weight and food intake [1], although the
importance of AgRP and NPY for body weight regulation is well
recognized. Thus, the phenotype of knockout mice does not always
Chapter 6
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correspond with the functional roles of the deleted protein. Therefore, the
improved melanocortin ligands will offer new possibilities to study the
central roles of MCRs.
Both JK1 and JK9 contain a substitution at the His6 position of the reference
peptide, which affected affinity and potency for the MC4R less than for the
MC3R and MC5R.Therefore, we concluded that mutations at this position
can be used to obtain MC4R selectivity. A number of recent studies
corroborate this notion. Bednarek et al. [2] found that substitution of His6 for
Pro in MTII increased MC4R selectivity and similar results were obtained
for other MTII-based compounds [3]. Holder et al. [4] also identified MC4R
selective agonists by substitution of the His6 position in Ac-His-D-Phe-Arg-
Trp-NH2 tetrapeptides. In most studies that describe effects of mutating
longer melanocortin analogues (7 or 13 amino acids), the imidazole group
of His6 was not found to be important for affinity and potency for MCRs
[2,5,6]. In smaller compounds consisting of the message sequence Ac-His-
D-Phe-Arg-Trp-NH2 , the role of the His position seems more important,
since its omission or substitution for Ala greatly reduces potency for MCRs
[4,7]. However, in these small compounds, other residues are also allowed on
this position [4,8], suggesting that presence of a residue is more important
than its exact side chain and that these requirements are more structurally.
Indeed, Lee et al have reported an altered conformation of an α-MSH
analogue that contained Lys6 [9].Thus, although the His6 of the endogenous
melanocortins seems not important for binding and activity itself, its position
can be used to hinder binding to MCR subtypes, probably by influencing
the conformation. Similar effects have been observed for position 10 of α-
MSH. Replacement in an α-MSH analogue of Gly10 for Asp, which is the
residue at position 10 in the MC3R-selective melanocortin γ-MSH, reduced
MC4R but not MC3R activity, while this residue probably does not interact
directly with residues in the receptor [10]. For development of MCR
subtype selective drugs, a general concept emerges from our own studies and
those described above. Key positions for binding to MCRs are Phe7,Arg8 and
Trp9, whereby substitution of Phe7 for D-Phe or bulky aromatic residues like
D-Nal(2) result in high potency or antagonism, respectively. Surrounding
residues can be used to direct selectivity for MCR subtypes, with position 6
being useful for obtaining MC4R selectivity. Since the message sequence is
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Figure 1. Effect of MC4R expression on
the vasopressin (AVP) response without
(squares) and with (triangles) 200 nM
AgrP(83-132). Cells were either
transfected with the human vasopressin-2
receptor (hV2R) alone (left) or in
combination with the hMC4R (right), and
responses were measured in the LacZ
assay as described in chapter 2. In the
presence of the hMC4R (as controlled for
by the α-MSH response, data not shown),
the maximal response of the hV2R to AVP
was increased. This potentiation was
inhibited by AgRP(83-132), which is an
inverse agonist for the hMC4R, but AgRP
did not influence the AVP response in the
absence of the hMC4R.AVP was ineffective
in inducing a response when only the
hMC4R was expressed (data not shown).
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thought to form a β-turn [11-13], cyclization may help to constrain
compounds into the favored conformation.
Selectivity of JK1 and JK9 for the MC4R in the activation assay was lower
than in the binding assay, and especially MC3R/MC4R selectivity was
moderate in the activation assay. One explanation for these observations may
be that JK1 and JK9 bind efficiently to the MC3R, but are poor competitors
for the tracer in the binding assay, giving an underestimation of MC3R
affinity. However, it has also been reported that the MC3R responds more
efficient than the MC4R in a reporter gene assay [9] and thus it is possible
that the potencies of JK1 and JK9 for the MC3R are overestimated in our
activation assay.
A number of MC4R selective agonists and antagonists have recently been
reported (Table I), most of them containing a modified His6 position. One
agonistic compound possessed 90-fold and more than 2000-fold selectivity
for the human MC4R over the MC3R and MC5R, respectively [14], but it
was not tested on the MC1R. A similar compound containing D-Nal(2)7
was found to be a selective MC4R antagonist [3]. High MC4R selectivity
over the MC3R and MC1R was obtained with a melanocortin-based
tetrapeptide in which His6 was substituted for Anc [4], but this compound
has also high potency for the MC5R.This shows that small ligands with high
selectivity and potency can be obtained for MCRs. Most studies have
concentrated on the MC4R, but a MC3R selective antagonist and weak
MC5R antagonists have now also been described [15,16]. As described in
chapter three, the MC5R may mediate the effects of exogenous
melanocortins on sensory recovery after peripheral nerve crush, and
development of selective MC5R ligands or MC5R antagonists would allow
to test the importance of this receptor for this process. Thus, the list of
selective melanocortin compounds is growing, which will certainly advance
research on the melanocortin system.
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Relevance of constitutive activity and 
inverse agonism
It has become clear that many G-protein coupled receptors (GPCRs) have
some degree of constitutive (agonist-independent) activity and that many
ligands, named inverse agonists, can suppress this basal activity. The
physiological relevance of these properties, however, has not been
determined yet. Our finding that the MC4R is constitutively active provides
another example of a wild type receptor that displays this property, and
AgRP is one of the first endogenous inverse agonist described, both adding
support to physiological relevance of inverse agonism. Interestingly, we have
data indicating that the MC4R has higher constitutive activity as compared
to several other GPCRs (Graeme Milligan, personal communication).This
tempts to speculate that constitutive activity is important only for a restricted
group of receptors, and the MC4R may be such a receptor.
If constitutive activity has physiological relevance, an obvious role would be
to maintain a basal tone of signal transduction activity without the need for
constant presence of agonist.The melanocortin system indeed exerts a tonic
inhibition on food intake [17], but this may largely be due to constant levels
of α-MSH, since it was blocked by the antagonist SHU9119. However, there
is another possible effect of constitutive activity by which it may affect
physiology, but which has not gained much attention. Many examples of
both inhibitory and stimulatory cross-talk between different receptor species
exist, occurring at different levels of the signal transduction pathway [18]. It
is conceivable that the constitutive activity of one receptor leads to a
different response of the cell to a ligand acting at a different receptor,
comparable to the potentiated forskolin response in the presence constitutive
activity (Chapter four). In this line of thinking, we have performed
experiments in which the vasopressin response of cells expressing the
vasopressin-2R was greatly enhanced by coexpression of the hMC4R
(Fig.1).This effect was blocked by AgRP, but AgRP did not influence the
vasopressin response in the absence of the MC4R, indicating that not merely
the presence of, but the constitutive activity displayed by the MC4R results
in the enhanced vasopressin response.A few reports have described cross-talk
effects of constitutive activity or inverse agonists. Berg et al. [19] reported
Chapter 6
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that pretreatment of cells expressing the 5-HT2C receptor with a 5-HT2C
inverse agonist, enhanced inositol phosphate accumulation induced by ATP
acting at P1 receptors that were also expressed on these cells. Another
example is the cannabinoid CB1R, which was shown to block other Gi
mediated responses of both G-protein coupled receptors and receptor
tyrosine kinases [20,21].The proposed model for this effect is that the CB1R
is constitutively active, and that the active form sequesters Gi proteins.The
inactive form of the CB1R that is stabilized by an inverse agonist was also
suggested to sequester Gi proteins, as the inverse agonist also blocked Gi
responses of other receptors.Therefore, physiological effects of constitutive
activity and inverse agonist may be mediated by modulation of other
receptor systems located in the same cell. Hypothetically, the response to
incoming (an)orexigenic signals of neurons that express constitutively active
MC4Rs may be affected by the release of AgRP.
There are several ways by which the physiological relevance of MC4R
constitutive activity and inverse agonism of AgRP may be studied. An
obvious method is to test the effect of AgRP in animals that are deficient of
endogenous melanocortins, like POMC deleted mice. If AgRP would show
efficacy in these animals, this would indicate that AgRP has in vivo functions
additional to antagonism of α-MSH. It is also possible to compare the in vivo
effect of MC4R antagonists with that of AgRP. A condition that should be
met, is that the antagonists have a similar profile as AgRP on all melanocortin
receptors to prevent differences in effect due to interaction of the antagonist
with another MCR subtype. Finally, if the in vitro cross-talk effects of
constitutive activity of the MC4R with other receptors as described above
can be further substantiated, the physiological relevance of constitutive
activity may be determined by studying cross-talk effects of AgRP in vivo.
It will be interesting to see whether endogenous inverse agonists also exist
for other receptors. The identification of agouti and AgRP was greatly
benefited by the fact that genetic models that lead to altered agouti
expression give phenotypes that are clearly visible (pigmentation and body
weight). Thus, agonist/inverse agonist combinations that regulate
concurrently one receptor similar to α-MSH and agouti/AgRP may well
exist for other systems, but their identification may be more difficult.
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Poor expression of MC4R mutants found in
obese individuals
Genetic studies have successfully identified several genes and chromosomal
locations involved in the development of obesity [22,23]. These findings
have increased our knowledge on the biological pathways of body weight
regulation in humans and provide potential targets for treatment of obesity.
Based on the biological role of the MC4R in rodents, this receptor is
considered an attractive candidate to be involved in the development of
human obesity. Indeed, several studies have tested for association of the
MC4R gene with obesity in humans.The outcome of these studies together,
is a group of rare heterozygous mutations in the MC4R gene which mostly
occur in the obese population. Because the mutations are rare, the evidence
for involvement of each individual mutation in obesity is not strong, in spite
of family studies that have been carried out. However, when the alleles can
be grouped on basis of functional or structural characteristics, association
may be shown for that group as opposed to the individual alleles. Of the
mutations that have been found both in obese as non-obese, at least two are
polymorphisms that apparently do not influence receptor function [24]. By
excluding these polymorphisms from the mutant group, the evidence for
association of MC4R mutations with obesity becomes much stronger.Thus,
functional studies on mutated proteins allow to differentiate between
mutations, and therefore can increase significance of association studies.The
study on the mutant MC4Rs as presented in this thesis suggest that these
mutants have impaired function, thereby strengthening a role of these
mutations in obesity.
As mentioned above, heterogeneity of phenotypes can hamper identification
of genes responsible for a disease. The MC4R mutations seem to occur
especially in cases of non-syndromic (non-diabetic) and early-onset obesity,
and females seem more severely affected [25]. Selecting obese subjects with
these characteristics may therefore be preferred when studying the role of
the MC4R in obesity.
The mutant MC4Rs that were tested here showed decreased cell surface
expression, most likely resulting in the decreased maximal α-MSH responses
that were observed. If decreased MC4R signaling due to impaired cell
Chapter 6
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surface expression is indeed the mechanism underlying the increased risk for
development of obesity in mutation carriers, these individuals should
theoretically benefit from treatment aimed at increasing this signaling.
Melanocortin agonists could therefore be a proposed therapy. However,
activation of GPCRs usually causes desensitization and eventually down-
regulation of receptor signaling, resulting in an attenuated response also for
the endogenous ligand.Agonists that do not cause desensitization or down-
regulation have been described [26] and may therefore be preferred. An
alternative way to normalize MC4R signaling may be to stabilize cell surface
expression. Up-regulation of (mutant) receptors has been observed upon
incubation with inverse agonist and antagonist (see [27]). Although it may
seem paradoxical to treat obesity with a MC4R antagonist or inverse
agonist, the long term effect of such treatment could still be advantageous.
This is indicated by studies in which β2-adrenergic receptor (βAR) blockers
increased survival in patients with impaired ventricular function (see [28]),
whereas on short term these blockers actually decrease heart function by
inhibiting cardiac βARs. One of the proposed mechanisms for these
unexpected beneficial effects in patients is that the βAR blockers normalize
the decreased βAR expression level, which is usually observed in these
patients. By doing so, the response to endogenous βAR agonists would be
improved at times when this response is needed.Although several aspects of
this example differ from the situation of individuals bearing a MC4R
mutation (e.g. the cardiac patients do not have a mutated receptor), these
studies indicate that cell surface expression is important, and therefore
regulation of this parameter may be very effective in treating disorders that
involve decreased receptor expression. Future studies should address the
question whether stimulation by MC4R agonists or regulation of MC4R
expression by antagonists/inverse agonists are suitable methods to treat
obesity, the outcome of which could influence the design of melanocortin
drugs.
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Melanocortines, zoals bijvoorbeeld α-melanocyt stimulerend hormoon (α-
MSH) en adrenocorticotroop hormoon (ACTH), beïnvloeden diverse
lichaamsfuncties, waaronder pigmentatie, steroïd productie door de bijnieren,
pijn en zenuwregeneratie na letsel. Recent onderzoek heeft aangetoond dat
melanocortines tevens belangrijk zijn voor regulatie van metabolisme en
lichaamsgewicht in ratten en muizen.Ook bij mensen lijkt dit het geval te zijn,
al zijn de aanwijzingen hiervoor minder sterk.
Melanocortines binden aan specifieke receptoren, melanocortine receptoren
genaamd. Deze receptoren worden geactiveerd als gevolg van het binden van
melanocortines,wat uiteindelijk leidt tot de verschillende biologische effecten.
Er zijn momenteel vijf melanocortine receptoren bekend, namelijk MC1R
t/m MC5R. Iedere receptor heeft een eigen expressiepatroon: zo komt
bijvoorbeeld de MC4R alleen in het zenuwstelsel voor, terwijl de MC1R in
melanocyten (pigment cellen) en cellen van het immuunsysteem zit.
Vanwege hun rol in diverse biologische processen vormen de
melanocortines en melanocortine receptoren potentiële aangrijpingspunten
voor nieuwe medicijnen tegen aandoeningen/ziektes die te maken hebben
met deze processen, zoals overgewicht en zenuwschade. Meer informatie
over de werkingsmechanismen van de melanocortines, zoals welke cellen en
melanocortine receptor(en) er bij betrokken zijn, is nodig voordat zulke, op
melanocortines gebaseerde, medicijnen kunnen worden ontwikkeld. Dit
proefschrift richt zich hierop, door de farmacologische eigenschappen van
de MC4R beter in kaart brengen en de rol van deze receptor in
neuropatische pijn, zenuwregeneratie en obesitas te evalueren.
Liganden die selectief aan een bepaalde receptor binden worden vaak
gebruikt om de functie van die receptoren te bepalen. Echter, voor de
melanocortine receptoren bestonden lange tijd slechts liganden die goede
affiniteit hebben voor meerdere melanocortine receptoren, en dus niet
geschikt zijn om één bepaalde receptor te bestuderen. Hoofdstuk 2
beschrijft de ontwikkeling van peptiden met selectiviteit voor de MC4R,
zowel agonisten als antagonisten. Door het systematisch muteren van een
basispeptide, werden een agonist en een antagonist verkregen met verbeterde
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selectiviteit voor de MC4R ten opzichte van de MC3R en de MC5R. Deze
studie leverde tevens informatie op over de structuur-activiteit relatie van
melanocortine liganden, wat bruikbaar is bij verdere ontwikkeling van
selectieve liganden, die de basis kunnen vormen voor medicijnen die werken
via MC receptoren. Het meest MC4R-selectieve ligand uit deze studie gaf
een versterking van koude en mechanische allodynie (allodynie: pijnsensatie
als gevolg van een prikkel die normaliter geen pijn zou veroorzaken) in een
model voor neuropatische pijn, wat een aanwijzing is dat de MC4R
betrokken is bij de effecten van melanocortines op neuropatische pijn. De
MC4R zou daarom mogelijk een aangrijpingspunt kunnen zijn bij
behandeling van neuropatische pijn.
Met behulp van een aantal van de selectieve peptiden werd tevens de rol van
de MC4R onderzocht in een model voor perifere zenuwregeneratie na
letsel. De resultaten van deze studie, die beschreven staan in hoofdstuk 3,
duiden erop dat de MC4R niet betrokken is bij de positieve effecten van
melanocortines op perifere zenuwregeneratie, zoals tot nu toe werd
verondersteld. Op basis van de resultaten is het aannemelijker dat de MC5R
hierbij betrokken is.Verder onderzoek dient aan te tonen of dit inderdaad
het geval is.
Alhoewel men er altijd van uit ging dat receptoren alleen geactiveerd worden
als gevolg van ligand binding, is het nu algemeen geaccepteerd dat receptoren
ook basale, ligand-onafhankelijke activiteit (constitutieve activiteit) kunnen
bezitten. Sommige liganden kunnen deze constitutieve activiteit
onderdrukken, en deze liganden worden nu geclassificeerd als inverse
agonisten. Het is nog onduidelijk in welke mate constitutieve receptor
activiteit en inverse agonisme van belang zijn voor de biologische functies van
receptor-ligand systemen. Echter, voor de ontwikkeling van medicijnen zou
inverse agonisme wel degelijk een relevante eigenschap kunnen zijn om voor
te testen.
Agouti-Related Protein (AgRP) is een natuurlijk voorkomend peptide, dat
mogelijk een inverse agonist is voor melanocortine receptoren. AgRP
blokkeert activatie van de MC3R en MC4R, en speelt daarmee een
belangrijke rol in de regulatie van metabolisme en lichaamsgewicht. In
hoofdstuk 4 wordt beschreven dat de humane MC4R constitutieve
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activiteit bezit, en dat AgRP inderdaad een inverse agonist is voor deze
receptor.Deze eigenschappen kunnen relevant zijn voor het functioneren van
het melanocortine systeem in de regulatie van metabolisme en
lichaamsgewicht.Tevens kan het bestaan van een natuurlijke inverse agonist
worden gezien als een aanwijzing dat inverse agonisme en constitutieve
receptor activiteit wel degelijk een biologische functie hebben, en niet slechts
artefacten zijn van in vitro studies.
Er zijn meer dan dertig mutaties in de humane MC4R geïdentificeerd,
waarvan het merendeel alleen bij mensen met overgewicht is gevonden. Dit
is een aanwijzing dat het hebben van een mutatie in de MC4R de kans op
het ontwikkelen van overgewicht zou kunnen vergroten. Als dit inderdaad
het geval is, is het te verwachten dat de mutaties een effect hebben op de
werking van de receptor.Van een aantal mutaties was in activatiestudies al
aangetoond dat ze resulteren in functieverlies van de receptor, maar in deze
studies werd niet gekeken naar andere aspecten van receptor functie, zoals
receptor expressieniveau en affiniteit voor a-MSH en AgRP. Hoofdstuk 5
beschrijft een uitgebreidere farmacologische karakterisering van elf
gemuteerde receptoren, waaronder een aantal die nog niet eerder
functioneel getest waren. Alhoewel er over het algemeen weinig effect van
de mutaties op affiniteit voor a-MSH en AgRP werd gevonden, vertoonden
alle geteste mutanten verminderde expressie aan het celoppervlak, wat
resulteerde in lagere maximale activatie door a-MSH. Deze resultaten
indiceren dat de beschreven MC4R mutaties leiden tot functieverlies van de
receptor, en maken het hiermee aannemelijker dat deze mutaties een rol
spelen in de ontwikkeling van overgewicht. Ook bij mensen lijkt de MC4R
dus betrokken bij de regulatie van lichaamsgewicht.Als functieverlies van de
MC4R inderdaad leidt tot overgewicht bij mensen met een MC4R mutatie,
zouden deze mensen gebaat kunnen zijn bij normalisering van MC4R
activiteit.
146
proefschrift wouter  04-02-2003  16:25  Pagina 146
Dankwoord
Het is ongeveer 2222 dagen geleden* dat ik als analist bij het RMI in dienst
trad, vers van het HLO. Ik had toen niet kunnen vermoeden dat ik op
datzelfde RMI ooit een promotieonderzoek zou afronden. En dan ook nog
eens tegelijkertijd met een AGIKO met wie ik een wel heel collegiale relatie
zou onderhouden. Ik wist geeneens wat dat betekende, AGIKO (iets met
diepvries?). Een hoop bijgeleerd dus, de afgelopen jaren, dat zeker. Ook op
niet-wetenschappelijk gebied was het een boeiende periode, niet in de
laatste plaats door de mensen die ik heb leren kennen.
Deze laatste pagina’s zijn natuurlijk bij uitstek de plek om een aantal
personen te bedanken die direct of indirect belangrijk zijn geweest voor het
welslagen van mijn onderzoek.
“Met Roger Adan, ik wil je graag uitnodigen voor een sollicitatiegesprek.”
“Oh, da’s goed.Wanneer?”
“Kun je nú?”
Zo verliep onze eerste, typerende kennismaking aan de telefoon. En ja, ik
kon.
Roger, jouw razendsnelle manier van denken en plannen maken, die soms
nauwelijks bij te benen is, vormde de stuwende kracht achter het onderzoek.
In de dagelijkse begeleiding was je even gedreven, en was er altijd ruimte
voor een korte of lange vraag. De persoonlijke en informele manier waarop
onze gesprekken verliepen waardeer ik zeer. Die zelfde informele sfeer was
ook buiten het werk te vinden: de oefensessies met de band waren altijd erg
leuk. Tenslotte, gefeliciteerd dat je op de valreep gepromoveerd bent tot
promotor. Jammer dat je niet ook mijn paranimf wilde zijn (“hooggeleerde
opponent, ook díe vraag speel ik door naar achteren”).
Willem Hendrik Gispen. Ongelofelijk, dat je ondanks jouw volle agenda toch
nog tijd vond mij te helpen bij het schrijven.We zaten tijdens onze discussies niet
altijd geheel op één lijn, en ik vergeet nooit het moment waarop je, met het
hoofd in de handen en wanhoop in de stem, zei:“wat ben jíj eigenwijs, hoe doen
jullie dat thuis?”.‘k Zal proberen er aan te werken. Ik vind je manier van denken
en werken inspirerend en heb er een hoop van opgestoken.
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Keith, de tijd en energie die jij in de experimenten hebt gestoken is enorm.
Zonder jou was dit proefschrift wellicht slechts een kaftje met een
dankwoord geweest. Zelfs op de vrijdagavond was je nog bereid proeven af
te ronden. Joderen was altijd een feest: samen gammastraling vangen op het
B-lab, en dan acetonitril snuiven. Je bent al die jaren een gezellige
kamergenoot geweest, en ik ben blij dat je mijn paranimf wil zijn. (en
benieuwd hoe jij het zal doen met de vragen die ik straks “naar achteren”
doorspeel.....)
Nienke. Mijn onderzoek speelde zich voornamelijk af op het niveau van
microliters, membranen en microscopen. Zodra het groter werd dan een cel
haakte ik af; dankjewel voor je hulp bij de dierexperimenten...
Rea, erg bedankt voor de kleur die je aanbracht in dit proefschrift (zie
achterzijde). Geweldig dat je, naast je werk vol ‘Rea’cties en ‘Rea’gentia, nog
de tijd en energie vindt om de opleiding tot makelaar te volgen. Ik wens je
daarmee alle succes voor de toekomst.
Rob Liskamp en John Kruijtzer. Zoals een proefschrift niet zonder
dankwoord kan, zo kan de farmacologie niet zonder liganden. Jullie leverden
de broodnodige grondstoffen voor mijn onderzoek, waarvoor dank.
Maarten, wij kennen elkaar al langer dan de kerktoren van Raalte hoog is
(en da’s hoger dan die van den Dungen!). Ik HLO, jij HLO. Ik Australië, jij
Australië, ik nieuw huis, jij nieuw huis. Ik promoveren, jij ... eh ... nog niet.
Dankjewel dat je me op mijn promotiedag als paranimf terzijde zal staan.
De Damesclub, Corine, Jaquelien en Ineke, ik waardeer het zeer dat ik
ondanks mijn genetische achtergrond toch lid mocht worden van de club.‘t
Was telkens weer een gezellig gastronomisch gebeuren. Chromosomaal
gezien is GJ in ieder geval een waardig opvolger, en hij kookt ook vast beter
dan ik.
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De Muziekclub van het laatste uur: Robbie en Sander. Na alle stukjes die
we samen ten gehore hebben gebracht, varierend van prachtige muziek tot
k....herrie, nu een klein stukje van mij aan jullie: dankjewel voor alle plezier.
Oma Han, bedankt voor alle vaste én extra oppasdagen tijdens deze drukke
periode. En voor de goulash op de dagen dat ik Merijn naar Vught kwam
brengen.
Cécile, enorm grote dank voor je hulp bij de lay-out. Je hebt er, ondanks je
eigen deadline (hm.... ‘dead’line bij de Living?), heel wat avonden werk in
gestoken. Ik heb nu niet alleen een fraai boekje, maar ben ook heel wat
meer te weten gekomen over de communicatiestoornissen tussen de Mac en
de PC.
Mijn ouders dank ik voor alle  mogelijkheden die ze me gegeven hebben
en hun nooit aflatende interesse en vertrouwen in de dingen die ik doe. Ik
kan alleen maar hopen dat ik net zo’n goede ouder zal zijn.
Deze onderzoeksperiode heeft me zoveel meer opgeleverd dan alleen een
promotie:
Dorien en Merijn: dankjewel dat jullie in mijn leven zijn gekomen.
Zo, en dan nu een biertje!
149
Dankwoord
proefschrift wouter  04-02-2003  16:25  Pagina 149
Curriculum Vitae
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Radewijns College  te  Raalte behaalde hij in 1990 het HAVO diploma en in 1992 het
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waarvan de resultaten beschreven staan in dit proefschrift.
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